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ABSTRACT
Development of a Tagged scFv Based Immunoprecipitation Method
for Protein-protein interaction Studies
Maria Rosa Valero Aracama
Knowledge of the interaction between proteins is necessary for understanding how the
cellular machinery operates. Multiple methods have been developed to study proteinprotein interaction, but only two have been able to provide large amount of information
for S. cerevisae protein-protein network. Due to the multiple spurious data coming from
these methods, there is a need of new complementary methods to improve confidence of
the interactions. A new method is developed in this dissertation where the protein
complexes are pulled down (immunoprecipitated) using tagged single chain antibodies
specific for one of the proteins. Different affinity tags are chosen as candidates for
immunoprecipitation and tested that they don’t interfere with the antibody-antigen
binding while remaining active and providing a clean purification in mild conditions.
Strep tag II is chosen to be used as a first step in a double tag immunoprecipitation
process, followed by purification using SV5 tag. Immunoprecipitation using the
described method is proved in a model system. Multiple single chain antibodies are
selected against proteins from a real system, Shewanella oneidensis MR-1, and checked
for specificity and diversity. These single chains are used in an immunoprecipitation
experiment.

Dedication:

This dissertation is dedicated to my parents.

iii

Acknowledgements:
I would like to take this opportunity to thank my advisor Professor F.L. King for
his guidance and support during the years of my PhD studies. His encouragement made
me realize that I was capable of obtaining a PhD and always supported me with the
decisions I took to change the course of my research. I would also like to thank Dr.
Andrew Bradbury and his group at Los Alamos National Laboratory for introducing me
to molecular biology and help me through out the course of my thesis. I want to thank
Leslie Chasteen for being a good friend and a continuous help with my experiments and
to Joanne Ayriss for being not only a great friend but for mentoring and teaching me from
basic lab-book keeping to experimental planning and analysis, all with great enthusiasm
and patience.
I also would like to thank to my friends in West Virginia, Carol, Nuria, Ana,
Natalia, Lei and in Los Alamos, Josemari, Virginia and Priya, for all the great times we
had together and all the encouragement I got in every moment of my dissertation.
But most of all I would like to thank my parents, Jose Luis and Isabel, and my brother
and sisters for believing in me. Every new goal I set was received by them with great
excitement and enthusiasm, never thinking that it was too high for me to reach, and
enjoying with me every little success along the way.
I specially want to thank Carmen, Luca and McNair for being an example of
happiness, strength and love. McNair, you helped me finish and I wish you were here to
celebrate together this and many future successes to come.
I finally want to thank my husband Cris for supporting me through good and bad
times, and to my two daughters, Clara and Rosa for making these years much more fun
iv

and being the reason to reach the end of the day with a big smile. Clara I want to thank
you for making me relax after some tough days when I was trying to find a path forward
on my work. Rosa I want to thank you for being a great baby while I was writing the
dissertation, I don’t think I could have done it without your smile from the other side of
the room.

v

Table of Contents
ABSTRACT........................................................................................................................ ii
Dedication:......................................................................................................................... iii
Acknowledgements:........................................................................................................... iv
Table of Contents............................................................................................................... vi
List of Tables ..................................................................................................................... ix
List of Figures ..................................................................................................................... x
Chapter 1.

Introduction................................................................................................. 1

1.1.
Protein-protein interaction: ................................................................................. 1
1.2
Protein-protein interaction study using single chain antibodies: ........................ 6
1.3
Single chain antibodies (scFvs): ......................................................................... 8
1.3.1
Structure of scFvs ....................................................................................... 8
1.4
Phage Display: .................................................................................................. 11
1.4.1
Selection cycle .......................................................................................... 14
1.5
Affinity Tags..................................................................................................... 15
1.6
Shewanella oneidensis MR-1:........................................................................... 18
1.7
References......................................................................................................... 20
Chapter 2.
Materials and Methods.............................................................................. 30
2.1
Biological materials: ......................................................................................... 30
2.1.1
Bacterial strains:........................................................................................ 30
2.1.2
Bacterial plasmids:.................................................................................... 30
2.1.3
Primers: ..................................................................................................... 30
2.1.4
Primers used for tag amplification............................................................ 31
2.1.5
Other primers: ........................................................................................... 32
2.2
Polymerase Chain Reaction PCR: .................................................................... 32
2.3
Antibiotic concentrations: (stocks 1000x concentrated)................................... 33
2.4
Restriction Enzyme Digestion of DNA ............................................................ 33
2.5
Ligation of DNA Fragments ............................................................................. 33
2.6
DNA Agarose Gel Electrophoresis................................................................... 34
2.7
DNA recovery from agarose gel ....................................................................... 35
2.8
Plasmid DNA preparation from Bacteria.......................................................... 35
2.9
Transformation of DNA (ligation or plasmid) into competent cells................. 35
2.9.1
Electrocompetent: ..................................................................................... 35
2.9.1.1 S.O.C. Recipe :.......................................................................................... 36
2.9.2
Chemical competent.................................................................................. 36
2.10 Selection of antibodies using streptavidin magnetic beads: ............................. 36
2.11 Immunotube selections: .................................................................................... 39
vi

2.12 PEG precipitation of phages ............................................................................. 41
2.13 Protein expression:............................................................................................ 41
2.13.1
Expression of proteins using IPTG as inductor ........................................ 41
2.13.2
Expression of proteins using autoinducing media .................................... 42
2.14 Periplasmic extraction protocol ........................................................................ 42
2.15 LSRII : .............................................................................................................. 44
2.15.1
parameters:................................................................................................ 44
2.16 SV5 ELISA ....................................................................................................... 44
2.17 SDS polyacrylamide gel electrophoresis .......................................................... 46
2.17.1
10x protein loading dye (10 ml): .............................................................. 47
2.17.2
Gel Code staining...................................................................................... 47
2.17.3
Silver staining ........................................................................................... 48
2.17.4
Gel transference into membrane (blotting):.............................................. 48
2.18 Beads for affinity tags:...................................................................................... 49
2.19 Tag purification; buffers and protocols: ........................................................... 49
2.19.1
Purification using Ni-NTA beads: ............................................................ 50
2.19.2
Purification with Strep-Tactin Beads:....................................................... 50
2.19.3 Purification with chitin Beads:.................................................................. 51
2.19.4
Purification with Amylose beads:............................................................. 52
2.19.5
Biological LP purification: ....................................................................... 53
2.19.6
SV5 purification using protein A tips (Phynexus):................................... 54
2.20 Preparation of Shewanella oneidensis MR-1 cell pellet ................................... 56
2.21 Kcoil-Alexa488 synthesis ................................................................................. 57
2.21.1
K coil sequence:........................................................................................ 57
2.21.2
Synthesis: .................................................................................................. 57
2.21.3
Deprotection/purification:......................................................................... 57
2.21.4
Regeneration of the thiol after extended storage: ..................................... 58
2.21.5
Attachment of the Alexa fluor: ................................................................. 58
2.21.6
Peptide identification: ............................................................................... 58
Chapter 3.
Vector construction and testing ................................................................ 60
3.1
Introduction....................................................................................................... 60
3.2
Amplification of affinity tags: .......................................................................... 61
3.3
Creation of expression vector for scFv-tag fusions (pRosa6):.......................... 63
3.3.1
Cloning of pDAN6:................................................................................... 65
3.3.2
Cloning of pRosa6: ................................................................................... 67
3.4
Cloning of the Tags into pRosa6: ..................................................................... 68
3.5
Evolution of the pRosa6 vector: ....................................................................... 71
3.6
Creation of pRosa 7: ......................................................................................... 72
3.6.1
Cloning of scFvs into the pRosa7 vector: ................................................. 76
3.4.1
Creation of pRosa8: .................................................................................. 79
3.5
Functionality of the Tags: ................................................................................. 80
3.7
Discussion ......................................................................................................... 86
3.8
Abbreviations:................................................................................................... 91
3.9
References......................................................................................................... 92
Chapter 4.
Selection and Analysis of scFvs ............................................................... 94
vii

4.1
Introduction:...................................................................................................... 94
4.2
Immunotube selection against RV2607:........................................................... 95
4.3
Selection against Shewanella antigens “in solution” ........................................ 98
4.4
Biotinylation: .................................................................................................... 99
4.5
High throughput selection of scFvs ................................................................ 104
4.6
High-throughput screening of scFv ................................................................ 107
4.6.1
Labeling of the single chains (K coil-Alexa 488):.................................. 108
4.6.2
Flow cytometry and ELISA analysis: ..................................................... 115
4.6.3
Cloning of the scFvs into the tag vector (pRosa8-scFv-strep)................ 124
4.7
Discussion ....................................................................................................... 127
4.8
Appendix to Chapter 4 .................................................................................... 133
Chapter 5.
Immunoprecipitation of protein complexes ............................................ 135
5.1
Introduction..................................................................................................... 135
5.2
Immunoprecipitation of D1.3-lysozyme and Hyhel-10 using strep tag II and
SV5 tag........................................................................................................................ 137
5.3
Immunoprecipitation of S.oneidensis MR-1 protein complexes .................... 141
5.3.1
Expression and purification of scFv-Tag fusions: .................................. 141
5.3.2
I.P. Experiment #1: ................................................................................. 142
5.3.3
I.P. Experiment #2: ................................................................................. 144
5.4
Discussion ....................................................................................................... 146
5.5
Conclusion: ..................................................................................................... 152
5.6
References....................................................................................................... 154
Curriculum Vitae: ........................................................................................................... 155

viii

List of Tables
Table 1-1 Technical differences on the two high-throughput methods for detection of
protein complexes ....................................................................................................... 3
Table 1-2. Characteristics of the ideal affinity tag for immunoprecipitation purposes .... 15
Table 1-3. Characteristics of the Tags used in this study ................................................. 17
Table 3-1: Cloned tags information. Including a scFv of 31 kD. ..................................... 62
Table 3-2: Fragments after NcoI and AgeI digestion ....................................................... 68
Table 3-3: Single chains information................................................................................ 76
Table 3-4: bead capacity and amounts used for the experiments. .................................... 81
Table 3-5: Fusions of G4 to tags and beads used to compare purifications and expected
interaction with the matrices..................................................................................... 82
Table 4-1. Shewanella proteins information (concentrations before dialysis) ................. 99
Table 4-2. Excess of biotin linker used for each protein ................................................ 100
Table 4-3. Antigen concentrations calculated by BCA assay......................................... 102
Table 4-4. Number of biotins per protein molecule for each of the antigens ................. 103
Table 4-5. Variation in concentration and washes between the three rounds of selection
................................................................................................................................. 106
Table 4-6. Ratio between numbers of colonies obtained from third round output over
antigen coated beads versus the one over empty beads (negative)......................... 106
Table 4-7: Antigens and microspheres used in flow analysis. (b- Stands for biotinylated)
................................................................................................................................. 108
Table 4-8: Analysis of binders by LSR II flow cytometec. Positive corresponds to the
number of scFvs with S/N three or larger............................................................... 118
Table 4-9: Summary of results from ELISA assays on Shewanella proteins ................. 122
Table 5-2. Components added in each of the I.P. experiments. Approximately 0.7µg of
each scFv was used and 1ml of S. oneidensis (1mg/ml)......................................... 144

ix

List of Figures
Figure 1-1 : General scheme of complex purification and identification in Ho and Gavin’s
methods ....................................................................................................................... 3
Figure 1-2. comparison of the precipitation methods in the literature and the one proposed
in this thesis................................................................................................................. 7
Figure 1-3. Full length antibody and detail of the binding site corresponding to the single
chain............................................................................................................................ 9
Figure 1-4. Microscopy picture of filamentous phage...................................................... 11
Figure 1-5. Phage life cycle .............................................................................................. 12
Figure 1-6:. ScFv antibody displayed on bacteriophage as a P3 fusion. .......................... 13
Figure 1-7: Phage display selection cycle......................................................................... 15
Figure 1-8. Microscopy picture of Shewanella................................................................. 18
Figure 3-1. Amplification of the tags by pcr; CBP, Strep-tag II, CBD, GST and MBP... 62
Figure 3-2. Schematic of the cloning process to engineer pRosa6. .................................. 64
Figure 3-3. Schematic of the creation of pRosa6 and fingerprint..................................... 66
Figure 3-4. Purified fragments of pET-28 (1) and pDAN6 (2) vectors, digested with
EcoRI and NcoI. Ligation of both fragments produce pRosa6................................. 67
Figure 3-5. Fingerprint of 4 colonies from pRosa6 ligation. Undigested (U), NcoI and
EcoRI digestion (N/E), EcoRI and ClaI digestion (E/C) .......................................... 68
Figure 3-6. Digestion of pRosa6-scFv-CBP, pRosa6-scFv -chitin, pRosa6-scFv -GST,
pRosa6-scFv -MBP and pRosa6-scFv -strep with NcoI and AgeI RE. .................... 69
Figure 3-7. Expression of pRosa6 vectors with different tags. Samples analyzed by SV5
Western blot and ELISA. Refer to Table 1 for sizes ................................................ 70
Figure 3-8. Evolution of the pRosa vectors ...................................................................... 71
Figure 3-9. Schematic of the mutation introduced to remove the BssHII site from the lacI
gene. .......................................................................................................................... 72
Figure 3-10. BssHII digestion of pRosa7 and pRosa6...................................................... 73
Figure 3-11. Diagram showing the extra R.S. found in the DNA encoding the MBP tag 73
Figure 3-12. pRosa7-scFv-chitin and pRosa7-scFv-strep vectors checked by digestion
with NcoI/EcoRI (N/E) and with BssHII (B) ........................................................... 74
Figure 3-13. pRosa7-scFv-MBP vector checked by digestion with XbaI/EcoRI (X/E)... 75
Figure 3-14. Mutagenesis on the MBP gene to remove the BssHII restriction site.......... 75
Figure 3-15. BssHII digestion in mutated pRosa7-scFv-MBP (mut), and non mutated
pRosa7-scFv-MBP.................................................................................................... 76
Figure 3-16. D.13 and G4 single chains digested with NheI and BssHII R.E; α-FITC
single chain digested with XbaI and NheI R.E ......................................................... 77
Figure 3-17. SV5 western and ELISA assay on the tagged single chains D1.3, 4M5.3 and
G4.............................................................................................................................. 78
Figure 3-18. ELISA assay in D1.3-tag fusions expressed from pRosa8 vectors.............. 80
Figure 3-19. schematic of the expressed protein-tag fusions............................................ 81
Figure 3-20. Schematic of the experiment designed to check for the affinity and
specificity of the tags ................................................................................................ 82
Figure 3-21. SDS-PAGE gel and SV5 western to prove the specificity of the affinity tags
and the possibilities to use them as purification tags................................................ 84
x

Figure 4-1. Schematic of immunotube selection: a)Incubation of phage-scFv library with
antigen coated immunotube, b) Removal of unbound phages, c) Wash in
immunotube to remove non-specific binders, d) Removal of wash buffer............... 95
Figure 4-2. pDpH5’/pDpH3’ amplification of ELISA positives ...................................... 96
Figure 4-3. BsTN1 R.E. digestion of the full length single chains. 2 different fingerprints
were identified. ......................................................................................................... 97
Figure 4-4. : SV5 westerns on clones G4 and G12 (marker: kaleidoscope Prestained
Standard (BIO-RAD))............................................................................................... 97
Figure 4-5. Schematic of interaction of antibodies with biotinylated antigens bound to
neutravidin beads ...................................................................................................... 99
Figure 4-6. Western blot analysis of the biotinylated antigens. Loaded approximately
200ng of each protein.............................................................................................. 100
Figure 4-7. SDS- PAGE analysis for protein quantification by colorimetry.................. 102
Figure 4-8. Schematic of the KingFisher® working principle. (From
http://www.thermo.com)......................................................................................... 104
Figure 4-9 Schematic of the KingFisher® instrument and plate set up for the selection of
scFvs ....................................................................................................................... 105
Figure 4-10:: Excitation of a Luminex bead with green and red lasers
(Luminexcorp.com). ............................................................................................... 107
Figure 4-11: Coiled coils ................................................................................................ 109
Figure 4-12: Coil mediated labeling of single chain....................................................... 109
Figure 4-13: Mass spectrometric spectra of the synthesized K coil, before and after
labeling.................................................................................................................... 110
Figure 4-14: Western Blot Analysis of purified single chain-E/K coil fusions.............. 111
Figure 4-15: pEP-scFv-E vector diagram ....................................................................... 112
Figure 4-16: BssHII/NheI digestion of scFv DNA from selections against proteins 1,
2,3,4,5...................................................................................................................... 113
Figure 4-17: Fingerprint of single chains coming from selections against Shewanella
antigen targets, 2, 3, 4, 5 ......................................................................................... 114
Figure 4-18: Schematic of a multiplex experiment......................................................... 116
Figure 4-19: Data output coming from LSRII representing a positive binding event for a
single chain selected against a Shewanella antigen. ............................................... 117
Figure 4-20: Fingerprint of single chains against antigen #4 that were positive in ELISA
shown besides the corresponding ELISA and flow signals. Background is
represented by an average of the signals coming from ubiquitin and neutravidin only
beads. 96 clones were tested by ELISA, 46 of them also by flow.......................... 119
Figure 4-21: Fingerprint of single chains against antigen #5 that were positive in ELISA
shown besides the corresponding ELISA and flow signals. Background is
represented by an average of the signals coming from ubiquitin and neutravidin only
beads. 96 clones were tested by ELISA, 46 of them also by flow.......................... 120
Figure 4-22: Fingerprint of positive single chains against antigen #1 represented beside
the ELISA signals. Each signal corresponds to the average of two replicates.
(Neutravidin coated ELISA plate and biotinylated antigen)................................... 121
Figure 4-23: ELISA against Shewanella cell extract using scFvs that were positive
against antigen #5. Each signal is the average of two replicates. ........................... 122

xi

Figure 4-24: BssHII/NheI digested fragments of pRosa8-strep vector and of single chains
against antigens #5 and #1. ..................................................................................... 124
Figure 4-25: Alignment and phylogenetic tree of amino acid sequences of single chains
selected against antigen # 1..................................................................................... 125
Figure 4-26: Alignment and phylogenetic tree of amino acid sequences of single chains
selected against antigen # 5..................................................................................... 126
Figure 4-27: Raw ELISA and flow cytometry data corresponding to the scFvs selected
against antigen #4. Flow data has been represented in two different graphs in order
to be able to use different scales. ............................................................................ 133
Figure 4-28: Raw ELISA and flow cytometry data corresponding to the scFvs selected
against antigen #5. Flow data has been represented in two different graphs in order
to be able to use different scales. ............................................................................ 134
Figure 5-1: Schematic of the double tag purification process. ....................................... 136
Figure 5-2: Gel quantitation of the purified single chains. Proteins were recovered at a
concentration of 0.3µg/µl (Strep-D1.3-SV5) and 0.1µg/µl (HyHel10-AP). .......... 137
Figure 5-3: SDS Page analysis of model complex immunoprecipitation, comparison of
double and single tag purifications. Left figure is the expected bands, right hand one
is the actual experiment. 1µg of each scFv and equimolar amounts of lysozyme was
added to 50 µl of cell extract. Elution from strep Tactin matrix was in 100µl and in
30 µl from the α-SV5 column. Samples were loaded in equal volumes (10 µl).
Controls of each component were added HyHel10 (1µg), α-SV5(2.5µg), D1.3 (3µg).
Gel was developed by silver staining (chapter 2: silver staining) .......................... 139
Figure 5-4: Purified scFvs against antigens # 5 and #1 in Western Blot and gel code
stained gel. B8 and A3 samples purified using Ni-NTA tips and all the others with
agarose beads in column. ........................................................................................ 141
Figure 5-5: SDS PAGE gel of I.P experiments. First lane marker, second, I.P. experiment
using protein #1 and specific scFvs, third, I.P. experiment using protein #5 and
specific scFvs. 1µg of each scFv was added to 10 ml of S. oneidensis (1mg/ml).
Samples were incubated over night with strep Tactin beads .................................. 143
Figure 5-6: Analysis of the Elutions produced in I.P. experiment #2. Figures 6A and 6B
correspond to samples 1-4 analyzed by SDS PAGE and stained with either
Coomassie Blue or Silver respectively. Samples 3 and 4 are those spiked with the
corresponding target protein for each scFv set. Figure 6C and 6D shows analysis of
samples 5 and 6 by Western Blot and silver staining respectively. Samples 5 and 6
were spiked with the corresponding non-target protein for each scFv set.............. 145

xii

Chapter 1. Introduction
1.1.

Protein-protein interaction:

After completion of the Human Genome project, it was realized that the genome
is composed of fewer protein-coding genes than had previously been thought1 2.The
proteome is much more dynamic than the genome, changing while it develops and due to
external stimuli. Proteins form complicated interaction networks in which they regulate
and support each other3

4 56

. Because interacting proteins are thought to be functionally

related at the cellular level7, knowledge of protein complexes provides insight into the
operation of the cellular machinery. Developing an improved understanding of the
molecular and functional circuitry connecting protein complexes in human cells, is the
basis of systems in biology and can afford benefits in medicine as well as in fundamental
biomedical sciences8.
Multiple methods for protein-protein interaction identification have been
developed, but the most widely used are the following:
•

Co-immunoprecipitation: The most common method used to detect and
purify protein-protein interactions. It is a variation of immunoprecipitation,
but in this case not only the antigen binding to the antibody is identified but
also other proteins interacting with it. Antibody interacts with a target antigen
from a cell lysate; antigen and antibody are precipitated usually by interaction
of the antibody with a protein A or G affinity matrix, washed, and eluted with
any other proteins bound in complex to the antigen.9 10 11 12 13
•

Pull-down: Same principle as immunoprecipitation but using tagged bait
proteins instead of antibodies14 15 to precipitate species of interest.
1

•

Yeast two hybrid: This method identifies the interaction between only
two recombinant proteins at a time, expressed in yeast cells. The
transcription factor is split into two fragments, a deoxyribonucleic acid
(DNA) binding domain (BD) and an activation domain (AD). Pairs of
proteins are expressed as fusions (‘hybrids’) of either of the domains. Any
interaction between them leads to the formation of a functional
transcription factor.16 17 18 19

•

‘In silico’ (computed): Computer based interaction predictions using
available experimental data and methods of prediction based on gene
context analysis.7 20

•

Crosslinking: Proteins are covalently linked using chemical crosslinkers
prior to isolation and identification of the interacting proteins21 22.

Two recent high throughput studies of multi-protein (more than two proteins)
complex composition have been carried out, using co-immunoprecipitation (as shown in
Figure 1.1), with the model organism Saccharomyces cerevisae by Gavin et a
et a

15

14

and Ho

, Both studies have provided an unprecedented amount of protein interaction

information23 using tagged S. cerevisae proteins as baits to generate complexes that are
subsequently identified using mass spectrometry. The main characteristics of each coimmunoprecipitation method used by Ho and Gavin are highlighted in Table 1.1.

2

tagged bait

a)

a) bait protein is tagged

tag

b) baits are precipitated along

bait

with any associated proteins in

b)

an affinity column
bait

c) purified protein complexes
are resolved in a one dimensional

c)

SDS-PAGE gel
d) bands are excised and digested
with trypsin, then analyzed by mass
spectrometry.

d)

protein 1
protein 2
protein 3
protein 4

analyze by mass
spectrometry and
bioinformatics

Figure 1-1 : General scheme of complex purification and identification in Ho and Gavin’s methods24

bait expression
purification
detection

Ho
overexpressed bait proteins
one-step purification (FLAG)
LC-MS/MS

Gavin
wild-type expression levels
two-step purification (TAP)
MALDI-TOF

Table 1-1 Technical differences on the two high-throughput methods for detection of protein
complexes

Ho’s method included the over-expression of bait protein to all ensure that the
protein complexes were captured and available for analysis. The disadvantage is that
over-expression of the bait protein could lead to the formation of artifacts because the
stochiometry of the bait protein might change. As a result, it is possible that the formation
of protein complexes with the bait may not occur. It is also possible that the protein
interactions occurring with the bait protein are not truly representative of the complexes
that are formed naturally. In an attempt to ensure bait proteins were produced with the
correct stochiometry, Gavin introduced a method to include the use of an endogenous
3

promoter that allowed bait proteins to be expressed at their natural level. However, the
disadvantage is that if the bait protein fails to express or if the expression levels are below
the critical level required for analysis, then the immunoprecitation experiment will fail.
Ho recovered the protein complexes using the FLAG25 affinity tag with a single
purification step. In contrast, Gavin’s method included a double purification method
(Tandem Affinity Purification)26

27

using calmodulin binding peptide and protein A.

Single purification allows the possibility of detecting transient protein interactions while
double purification produces purer complexes with very low background.28 Because of
the high degree of specificity conferred by the tandem affinity purification, stringent
washes are not necessary, more effectively preserving less stable protein complexes29.
The protein complexes were detected using either liquid chromatography coupled
with tandem Mass Spectrometry (Ho’s method) or MALDI-TOF (Matrix-Assisted Laser
Desorption/Ionization-Time-of-Flight i.e. Gavin’s method).
Although both reported methods captured and identified hundreds of S. cerevisae
protein complexes, the consistency of the compared data was poor. Similar
inconsistencies were found when comparing results obtained using other methods such as
the yeast two-hybrid technique18 19.where only pairs of proteins, and no complexes, are
identified. These inconsistencies can be explained by the fact that each method
investigates different properties of the protein complexes. Therefore the data obtained is
more useful as a collective resource, providing complementary information that could
lead to a more complete biological overview when integrated8. Other studies, where
multiple methods are compared, estimated that more than half of all current highthroughput data are spurious. This suggests that to improve confidence in detected or

4

predicted protein interactions it is necessary to use as many different but complementary
methods as possible.17
Both methods described by Ho and Gavin require the introduction of a genetic
modification to the bait protein. The bait protein is expressed as a fusion to an unnatural
protein tag in order for the protein complex to be captured for analysis. When studying
protein-protein interactions it is best to form the complexes in conditions as near to their
natural state as possible. Modification of the bait proteins with a tag fusion can be
problematic as it is possible that the modification could affect protein conformation and
ultimately generate unnatural or false protein complexes.

5

1.2 Protein-protein interaction study using single chain
antibodies:
The standard co-immunoprecipitation method (described in Figure 1.1) is an
invaluable tool for the capture, detection and analysis of protein complexes. However, the
method could be further improved by allowing the bait protein to remain in its natural
state by eliminating the requirement to pair it with a tag for capture of the protein
complex. The aim of this project is to introduce and research a new method that allows
the bait protein to remain in its natural conformational state during complex formation.
This proposed method includes the capture of the protein complex via a tagged single
chain antibody (scFv) that is specific for the bait protein. A schematic of the proposed
method is described in Figure 1.2-1. The characteristics of this proposed method are:
-

There is no genetic modification of the bait protein, as no tag is required

-

Bait protein is not over expressed so real stochiometry is conserved

-

Complexes are double purified providing a cleaner final product

-

This method is amenable to high throughput analysis

6

Proposed
method

Methods in
use
tagged

tagged
SV5

tag
bait

strep tag II

bait

protein 1
protein 2
protein 3
protein 4

bait

analyze by mass
spectrometry and
bioinformatics

protein 1
protein 2
protein 3
protein 4

Figure 1-2. comparison of the precipitation methods in the literature and the one proposed in this
thesis.
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1.3 Single chain antibodies (scFvs):
Antibodies are proteins that are produced by B-cells, of the immune system, in
response to a target antigen (a protein or polysaccharide to which an antibody binds).
Immunization of a mammalian host with target antigen stimulates an array of different Bcells to make different antibodies thus producing polyclonal antibodies. Polyclonal
antibodies comprise of a mixture of multiple different antibody binders; where each
different binder recognizes a different epitope on the same target antigen. The production
of polyclonal sera is not reproducible even when it comes from the same animal.30 It is
also a source of high background as sera contain the entire repertoire of antibodies found
in the host animal at the time it was collected.31
Monoclonal antibodies are produced using hybridoma technology32. Hybridomas
are generated from a single B-cell fused to a cancerous immune cell (myeloma cell).
Individual hybridoma cells produce the same monoclonal antibody that recognizes the
same epitope on the target antigen. Monoclonal antibodies can present problems of
toxicity30 at the high doses required to deliver sufficient antibody to the site of the tumor,
can show poor penetration on tumor masses and can induce human antimouse antibody
responses.33

1.3.1 Structure of scFvs
Immunoglubulins are naturally occurring antibodies that are comprised of two
light and two heavy polypeptide chains connected by disulfide bonds. Each of the four
heavy and light chains has a constant and a variable region. The constant region provides
the effector function to the antibody, while the variable region is responsible for antigen
binding. ScFv antibodies are genetically engineered fusions comprising the variable
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regions of an antibody variable light-chain (VL) attached to a variable heavy chain (VH)
by a polypeptide linker from the carboxyl terminus of the VL sequence to the amino
terminus of the VH sequence46 34 or vice versa (VH-VL). The scFvs are correctly processed
and are soluble45 in the oxidizing environment of the periplasm as they contain
intramolecular disulfide bonds which are required for their stability.

Full length antibody
IgG2a

VH

VH
VL

VL
CH1

CH1

CL

CL

VH
VL

Fv

linker

Fc

scFv
(25 kD)

CH2 CH2

CH3 CH3

Figure 1-3. Full length antibody and detail of the binding site corresponding to the single chain

ScFvs are utilized in multiple applications including tumor targeting in vivo35

36

,

HIV testing of serum37, selection of antibodies against toxic antigens38, removal of toxic
agents34, antibody micro-arrays39

40

, identification of unknown cellular receptors41,

detection of infection and potentially block pathogenesis

42

and as a vehicle for drug

delivery.43
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Single chain antibodies (scFvs) were initially developed by two separate groups46
44

as the smallest fragments45 having the same specificities and affinities for their antigens

as the parent monoclonal antibody46.
Some advantages of the use of scFvs versus the use of monoclonal antibodies
are:47 48
•

Lower production costs.

•

Higher capacity for antigen on weight basis.

•

Rapid and uniform penetration in small pore matrix.

While disadvantages are:
•

Decreased stability.Short half lives.

•

In some cases have lower affinities to the antigen than IgGs due to the
linker interfering with the binding49.

A mixture of different scFvs selected against a target antigen will produce stable
multivalent interactions being equivalent to those observed by polyclonal antibodies. At
the same time, background will be reduced. One of the problems with monomeric
antibodies is their varied affinities for protein A; which is normally used to precipitate the
complex. Using a tagged scFv will assure the same affinity independently of the scFv.
Using pools of different scFvs in immunoprecipitation will take advantage of the
properties of both polyclonal and monoclonal antibodies.
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1.4 Phage Display:
Filamentous bacteriophages (Genus Inovirus) are viruses that contain a circular
single- stranded DNA genome encased in a long protein capsid cylinder50.

Figure 1-4. Microscopy picture of filamentous phage51

The Ff bacteriophage infects E. coli bacteria via the F pili found in those E. coli
strains that contain the F plasmid. The Ff phage does not kill the host but rather induces a
state in which the infected bacterium produces and secretes phage particles54. Stages of
phage life cycle: Bacteria are infected via the F pilus, viral genome is replicated, new
viral particles are assembled and the progeny particles are released from the host.
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Figure 1-5. Phage life cycle52

The bacteriophage genome consists of 11 genes of which 5 encode coat proteins
and the remaining six are involved in phage maturation inside the bacterial cell. The
single major coat protein is encoded by gene VIII whereas 4 additional genes encode the
minor coat proteins; pIII, pV, pVII and pIX.
Smith first introduced phage display in 198553 as a molecular diversity technology
that allowed display of large protein or peptide libraries on the surface coat protein of
filamentous phage54. DNA encoding the protein of interest is fused to the DNA encoding
the phage-coat protein. Following infection into the host bacterial cell, the phage particle
is packaged and, as a result, the protein of interest is displayed upon the surface of the
bacteriophage. Out of five coat proteins, the gene 3 protein (pIII or p3) is the one most
commonly used for display55 being present in up to 5 copies per phage (Refer to Figure 16)
12

Figure 1-6:. ScFv antibody displayed on bacteriophage as a P3 fusion.

The large scFv phage display library used for the work presented in this thesis was
developed by Sblattero and Bradbury56. VH and VL genes were amplified by PCR from
complementary DNA (cDNA) derived from human blood lymphocytes. Individual VH
and VL genes were joined via a short DNA linker containing a lox recombination site
using PCR primers57 and the subsequent primary library was created by cloning the
assembled VH and VL fragments into the pDAN5 vector. The secondary library was
created by shuffling the individual VH and VL genes by recombination and creating new
VH and VL functional combinations. As a result of recombination, the diversity of the
final tertiary scFv library is increased. In the final tertiary library, the genotype (DNA)
and phenotype (displayed protein) are coupled ensuring that the gene within the phage
encodes the scFv displayed on its surface, and providing the advantage that the scFv can
be fused to other proteins or tags

13

1.4.1 Selection cycle
The selection cycle is a technical process designed to recover one or more unique
proteins that specifically bind to the target antigen. Specific antigen binding clones are
recovered from the antibody phage library by a process called ‘panning’. In this
technique the phage library is incubated with a target antigen that is bound to a surface
either directly or by a ligand (e.g. streptavidin)58

59

. Unbound antibodies are washed off

and bound ones are eluted, amplified and used as input for the subsequent selection cycle
(Refer to Figure 1-7). During the panning process, the stringency of washes can be
increased and the amount of target antigen decreased from one selection cycle to the next
in order to enrich for the population with desired binding characteristics. Following three
rounds of selection, the eluted clones are recovered and analyzed, by either ELISA or
flow cytometry, for antigen binding. The aim of the panning process is to ‘select’ and
‘enrich’ for those scFv clones that bind specifically to the target antigen.
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Phage display selection cycle
Display variants on surface of phage
Bind phage
DNA
manipulation to
create library of
mutants

Wash

Amplify

Elute

Analyze binding
properties of scFv antibodies

Figure 1-7: Phage display selection cycle

1.5 Affinity Tags
One of the aspects of this work was to study the effect of expressing scFv proteins
as fusions with different protein affinity tags, the goal of which was to discover tags
which could be used in immunoprecipitation. It was necessary to demonstrate that the
scFv proteins retained their specific antigen binding properties when fused to the affinity
tags, for the recovery of intact protein complexes following immuno-precipitation.
Initially the tags were chosen for their biochemical properties that allowed the protein
complex to be recovered by treatment with mild elution buffers.

Properties of the ideal affinity tag for I.P.
has small size
is easily eluted
has minimal effect on binding activity
doesn’t hinder or enhances expression and/or folding

Table 1-2. Characteristics of the ideal affinity tag for immunoprecipitation purposes
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Affinity tags are normally used to aid in the expression and purification of
recombinant proteins60. There are basically two varieties of affinity tags: small peptides
and larger proteins or protein domains. Small peptide tags are mainly used as purification
tags whereas proteins or large peptide tags are used to enhance some characteristics of the
fused protein, solubility for example. The use of a small peptide tag assures no
interference with the fused protein or any other proteins that the fused protein is in
complex with. Some of the most commonly used small peptide affinity tags include His
tag61, myc tag62, Flag epitope63, Strep tagII64. Polyclonal and monoclonal antibodies have
been raised against many of these tags, including the Flag epitope and myc tag. Because
the elution conditions required to disrupt the antibody/peptide tag interaction are harsh,
their use as the first step in a double purification process would not be ideal, as all the
protein-protein interactions would be disrupted.
SV5 is a small tag that has been used for protein purification65 but is more
generally used as a detection tag in ELISA or Western Blot assays. The SV5 tag is
recognized by the monoclonal anti-SV5 (SV5-P-k66) antibody with high affinity and
requires harsh buffers and denaturing conditions to disrupt the protein-protein complex
for elution.
Protiens or protein domains are usually used to aid protein purification
(Glutathione S-transferase tag67, protein A68, cellulose binding domains69), improve
protein expression levels (Calmodulin-binding peptide70, chitin binding domain71) or
increase the solubility of the fusion partner72 (maltose binding protein73, thioredoxin74).
All have high specificity for their matrices.
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ScFv proteins are known to poorly express, have a tendency to aggregate and are
not very stable75. In order to aid scFv production, maltose binding protein (MBP),
Glutathione S-transferase tag (GST), chitin binding domain (CBD) and calmodulin
binding peptide (CBP) tags were chosen as fusion tags to improve the expression and
stability of the scFv proteins recovered in this study, in addition to allowing purification
using mild elution conditions. Strep tag II was also chosen as a purification tag as it has a
very high specificity for its matrix but requires mild elution conditions. It is known to
produce highly pure products at moderate cost76. Due to the small size of Strep tag II
(2.5kDa), it would not be expected to affect the functionality of the scFv through steric
hinderence. Studies have demonstrated that the Strep tag II remains functional and does
not affect the binding properties of scFv protein independently of the terminus that it has
been fused to.77

78

Table 1-3 summarizes the main characteristics of the affinity Tags

used in this study.
tags
size(kD)
MBP
40
GST
26
CBD
7.7
CBP
4
Strep tag II
2.5

elution
maltose
reduced glutathione
EGTA
biotin

commentaries
enhances solubility, large
mild elution, forms dimers
cannot be eluted, good 2nd step
high specificity
high specificity

Table 1-3. Characteristics of the Tags used in this study

The expression vector pRosa (refer to Chapter 3) was constructed for this study to
allow the Tags to be cloned either upstream (N-terminus) or downstream (C-terminus) of
the scFv protein. All of the Tags used in this study were cloned upstream of the scFv
protein, as N-terminal affinity tags are known to improve the yield of recombinant
protein by providing a reliable context for efficient translation initiation.79 Functional
characterization of recombinant protein affinity tag fusions was required, because some
17

tags have been proven to negatively affect protein function depending on the terminus to
which they are fused. For example, MBP behaves a as a solubility enhancer only when it
is expressed as an N-terminal fusion.80

1.6 Shewanella oneidensis MR-1:
Shewanella oneidensis MR-1 (S. oneidensis) is a bacterium that can grow
aerobically or anaerobically, using different electron acceptors81. This bacterium
enzymatically reduces metals and radio nuclides altering their ionic properties, which
affects their solubility and the solubility of other potentially harmful chemicals in their
proximity. It is widely distributed in the environment and is harmless to humans or any
other organism. These characteristics make S. oneidensis a main candidate for future bioremediation efforts. Shewanella oneidensis MR-1 was initially isolated from the
anaerobic sediments of the Oneida Lake in New York State in 1988 by Myers and
Nielson82 whereas other species have been isolated from marine sediments, marine
waters, and a variety of other environments83.

Figure 1-8. Microscopy picture of Shewanella84

The genome of Shewanella oneidensis MR-1 is comprised of approximately 5000
genes and has been recently sequenced and published85 but little is known about how it
18

operates at a cellular level. A federation (Shewanella Federation) was formed to enable
the sharing of information among investigators and thereby, to enable a better
understanding of the microorganism at a whole-system level81.
The aim of this research project is to develop a novel immunoprecipitation
method that can be used to generate and identify protein complexes. The rationale of the
immunoprecipitation method is different to those currently described for multi-protein
complex analysis. The method involves the generation of ‘Tagged’ single-chain (scFv)
antibodies (using phage display) against a target antigen in order to recover a final protein
complex for analysis. All components of the proposed immunoprecipitation method were
tested to ensure that they were functional. A proof of principle immunoprecipitation was
performed with a known antibody and antigen complex and the system was then applied
to the generation and capture of S. oneidensis complexes. The proposed method can be
used to generate data that compliments information generated from other IP experiments;
where the bait protein is tagged and used to pull down the complexes for subsequent
analysis.
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Chapter 2. Materials and Methods
2.1 Biological materials:
2.1.1 Bacterial strains:
E. Coli Strain

Genotype

Use

Supplier

propagation of phage

Invitrogen

F’/endA1 hsdR17 (rk- mk+) supE44
thi-1
DH5αF'

BL21(DE3)(gold)

recA1

(Nair)

gyrA

(lacZYA-argF)

U169

relAI
deoR

( 80dlac ) lacZ)M15)

recombinant cloning

E.coli B F¯omp hsdS (rb¯mb¯) dcm

recombinant sub cloning

Tetr, gal λ (DE3) endA Hte

Protein expression

Stratagene

Protein expression

Stratagene

E.coli B F¯omp hsdS (rb¯mb¯) dcm
Tetr
BL21(DE3)(gold)pLysS

gal λ (DE3) endA The [pLysS Cam]

2.1.2 Bacterial plasmids:
plasmid

Use

supplier

pET-28b(+)

protein expression

Novagen

Pmal-p2x

cloning MBP tag

New England Biolabs

pET-42

cloning GST tag

EMB biosciences

pET-32

cloning Thrx tag

EMB biosciences

pTYB1

cloning Chitin tag

New England Biolabs

2.1.3 Primers:
They were either supplied by Operon technologies or by MWG.
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2.1.4 Primers used for tag amplification
Sfi-Tag

GCAGGGGCCGCCCTGGCC + bp’s from beginning of tag
GCAGGGGCCGCCCTGGCCGCAGAAAAGAGAAGATGG AAAAAGAAT

SfiI-CBP
TTCATAGCCGTCTCAGCAGCCAACCGC TTT
SfiI-MBP

GCAGGGGCCGCCCTGGCCGCCGCCAAAATCGAAGAAGGTAAAGCA

SfiI-GST

GGGGCCGCCCTGGCCGCGTCCCCTATACTAGGTTATTGG
GCAGGGGCCGCCCTGGCCGCGAGCGATAAAATTATTCACCTGCTGG

SfiI-Thrx
TAATC
GCAGGGGCCGCCCTGGCCGCAGCTTGGAGCCACCCGCAGTTCGAA
SfiI-strep
AAA
SfiI-chitin

GCAGGGGCCGCCCTGGCCGCGACGACAAATCCTGGTGTATCCGCT
Last bps of the tags + GGAGGCGGTTCAGGCGGAGGTGGCTCTGGCG

AgeI-Tag
GT+ ACCGGTCCGG
CCGGACCGGTACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCAA
AgeIGTGCCCCGGAGGATGAGATTTTCTTAAAGCGGTTGGCTGCTGAGACG
CBP(rc)
GC
AgeI-

CCGGACCGGTACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCAG

MBP(rc)

TCTGCGCGTCTTTCAGGGCTTC

AgeI-

CCGGACCGGTACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCAT

GST(rc)

CCGATTTTGGAGGATGGTCGCC

AgeI-

CCGGACCGGTACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCGG

Thrx(rc)

CCAGGTTAGCGTCGAGGAACTC

AgeI-

CCGGACCGGTACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCTT

strep(rc)

TTTCGAACTGCGGGTGGCTCCA

AgeI-

CCGGACCGGTACCGCCAGAGCCACCTCCGCCTGAACCGCCTCCTT

chitin(rc)

GAAGCTGCCACAAGGCAGGAAC
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2.1.5 Other primers:
T7 promoter
T7 terminator
pDpH5'
pDpH3'
lacIseq
lacmid5
lacseq3
LacIEcorVlong
LacIMluI3'
pelBSfiI
pelBNcoI
LacI
LacImut
MBPmutg5
MBPmutgnew3
Fwdantifluor
Revantifluor
MBP5 for sequencing

TAATACGACTCACTATAGGG
GCTAGTTATTGCTCAGCGG
GCAGCCGCTGGATTGTTATTA
TTGTCGTCTTTCCAGACGTTA
CACCGGAAGGAGCTGACTGGGTTG
ATCCTGGTCATCCAGCGGATAGTT
AGCCCAGTAGTAGGTTGAGGCCGTT
TCGTATCCCACTACCGAGATATCCGCACCAACGCGCAG
CCCGGACTCGGTAATGGCA
TCTCGCGCAACGCGTCAGTGGGCTGATCATTAACT
GGCATGCGCGCCACCGGTCTCATCTTTATAATCGGCCAG
GGCGGCCCCTGCTGCGAGTAATAA
AAGCTTGCCAAATTCTATTTCAAGGAGACAGTCACCATGG
AATACCTATTGCC
CGCATTGCGCCCAGCGCCATCTGATCGTTGGC
AGATGGCCATTACCGCGCTGGGCGCAATGCGT
GAAAGCGAAAGGTAAGAGCGCTCTGATGTTCAA
GCGCTCTTACCTTTCGCTTTCAGTTCTTTAT
GCTCATGCGCGCATGCCGTCGTTATGACTCAAACACCAC
TATC
CGATACTCTAGAGGAGACGGTGACTGAGGTTCCTTG
GATAACGCTGGCGCGAAAGCGGGT

2.2 Polymerase Chain Reaction PCR:
PCR was performed using BioRad 8-Tube Strip CLR pcr tubes. The final volume
of the reaction was usually 20 µl, but scaled up in the case of need of larger amounts for
further cloning. The pcr master mix was prepared on ice and the general recipe included
500 nM of each primer, 250 µM of each dNTP, 0.1 units of the polymerase (Vent (NEB,
2000 u/ml), ex-Taq from TAKARA or NEB taq), proof reading polymerase was used in
the cloning steps, 1x of pcr buffer and in the case magnesium was not into it, it was added
to a final concentration of 2.5 mM. The target DNA was added in amounts up to 1 ng of
plasmid. In the case of using colonies to do pcr on their DNA, each one was picked with
a sterile tip and transferred into a sterile pcr tube containing 50 µl of 2xty media. 3 µl of
this media was used as target DNA. The mix was adjusted in volume with sterilized
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double distilled water. All amplifications were performed using a MJ Research PCT-200
Peltier Thermal Cycler with the following profile: - initiation at 95°C for 4 min followed
by 1 min at 92°C for denaturation, annealing at optimum temperature (45-65°C) for 1
min and extension at 72°C for 1 min per kbp of final product. The cycle from
denaturation to extension was then repeated 29 more times. At the end of the cycles, a
final step at 72°C for 5 min was carried out and then it remained at 4°C until taken out of
the machine.

2.3 Antibiotic concentrations: (stocks 1000x concentrated)
Carbenicillin: 50µg/µl
Kanamycin: 50µg/µl
Tetracycline: 15mg/ml

2.4 Restriction Enzyme Digestion of DNA
DNA was digested with restriction enzymes according to the manufacturer’s
instructions.

2.5 Ligation of DNA Fragments
DNA fragments were ligated in a 10 µl reaction mix containing; 3 units of T4 DNA
ligase (Promega), 1x T4 ligation buffer, cut vector/insert DNA (concentration between
100-250 ng) in a molar ratio of 1:3 and de-ionized water to make up the final volume.
Ligation samples were incubated at 16°C for 16-20 h and stored at 4°C prior to use. The
ligation mix was added directly to competent E. coli cells for transformation
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2.6 DNA Agarose Gel Electrophoresis
This method was used to quantify and characterise DNA that had been extracted,
purified, digested with restriction enzymes and amplified via PCR. Agarose
(electrophoresis grade; Gibco BRL® Life Technologies) gels between 0.7-1.2% (w/v)
were made with 1XTAE buffer containing 0.5 µg/ml of ethidium bromide (EtBr). DNA
samples were mixed with 10 x DNA loading dye (recipe follows) and loaded into the
agarose gel submerged in 1 x TAE buffer. A voltage of 1-5 V/cm was applied until the
DNA had migrated to the desired position. DNA products were sized against Lambda
HindIII (Promega) and phiX Hae III DNA ladder (Promega) markers. DNA Products
were visualised with Syngene BioImaging with GeneSnap software from SynGene.
50x TAE (Tris-acetate) (1L)
• Dissolve 242 g Tris in 500 ml H2O
•

Add 100 ml 0.5 M Na2EDTA (pH 8.0) and 57.1 ml glacial acetic acid

•

Adjust volume to 1liter with H2O

•

Store at room temperature

10x DNA loading Dye: Final concentrations:
• 50%glycerol
•

0.1% Bromophenol blue (BB)

•

0.1% Xylene Cyanole FF (XC)

For 10 ml:
•

1 ml 1% BB 1ml 1%

•

XC 5 ml 100% glycerol

•

3 ml 2xdH2O
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2.7 DNA recovery from agarose gel
DNA was recovered using the QIAquick™ Gel Extraction Kit (Qiagen) according
to the manufacturer’s instructions.

2.8 Plasmid DNA preparation from Bacteria
Plasmid DNA (up to 20 µg) was purified from E. coli small-scale culture using the
QIAprep® Spin Miniprep Kit (Qiagen). DNA was recovered according to the
manufacturer’s instructions.

2.9 Transformation of DNA (ligation or plasmid) into
competent cells
In-house Cells normally used:
•

Chemically competent (DH5aF- T) = 2X10e8

•

Electrocompetent (BL21 DE3) 2.5 X10e10

2.9.1 Electrocompetent:
Set the electroporator, BTX Harvard Apparatus Electro Cell Manipulator ECM630
Bio Rad Gene Pulser II and BioRad Pulse Controller II, with the following settings:
•

Voltage: 2500V HV

•

Resitor: 200 Ω

•

Capacitor: 25 µF

Place electroporation cuvettes (BTX Electroporation Cuvettes Plus 2mm Gap) on ice.
Place 50µl of electro-competent competent cells inside of the cuvette. Add carefully
DNA to the cells (1-10 ng plasmid DNA). Electroporate and add 500 µl of S.O.C.
Incubate for one hour at 260 rpm and 37°C.
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2.9.1.1 S.O.C. Recipe :
Difco SOB medium+ 20mM Glucose
Sterilize by autoclaving

2.9.2 Chemical competent
-Place 20 µl of chemically competent cells into tube ( Fisherbrand Culture Test Tube
12X75mm polystyrene with cap) while on ice. Add DNA and incubate in water bath at
42°C for 30s. Incubate in ice for two minutes. Add 200 µl of S.O.C. Incubate for one
hour at 260 rpm and 37°C.

2.10 Selection of antibodies using streptavidin magnetic beads:
The selection process was done using KingFisher® (Thermo-Labsystems)
Consumables/Reagents Required for selection
-

1xKingfisher 96 well plate (thermo-Labsystems, #97002080, 100 pieces)

-

1x KingFisher Tips Combs (thermo-Labsystems, #97002070, 50 pieces)

-

Dynabeads (Streptavidin M-280 magnetic beads,6.7 x 10^8 beads/ml, #112.06)

-Wash buffer 1xPBS-T (0.1% tween 20). 100 ul of 50%Tween in PBS in 50 ml 1xPBS.
Filter
-Wash buffer 1x PBS-LT (0.01% tween20). 10 ul of 50%Tween in PBS in 50 ml 1xPBS.
Filter
-Elution buffer: 0.1M HCl
-Neutralizing buffer: 1.5 M Tris pH=8.8
Beads and library preparation prior to selection:
Beads:
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-

30ul of beads are required for each sample tested

-

wash twice with PBS-T

-

resuspend each set in 200 µl of PBS-T

Blocking of the library
-

2% BSA . 1g in 50 ml H2O.

-

Block the library using 2% BSA (stock conc.) in PBS-LT.

-

per sample 100 ul library+ 37ul PBS-LT+ 34ul 2%BSA.

-

which will mean 1.0 10^2 cfu in 100ul and 0.4%BSA final.

Block rotating at RT for 1 hr.
KingFisher plate:
The plate was set up for selection as shown in the diagram

A
B
C
D
E
F
G
H

prot# 1
antigen
+φ
empty beads
PBS-T
PBS-T
PBS-LT
PBS-LT
PBS-LT
0.1M HCl

prot# 2
antigen
+φ
empty beads
PBS-T
PBS-T
PBS-LT
PBS-LT
PBS-LT
0.1M HCl

prot# 3
antigen
+φ
empty beads
PBS-T
PBS-T
PBS-LT
PBS-LT
PBS-LT
0.1M HCl

prot# 4
antigen
+φ
empty beads
PBS-T
PBS-T
PBS-LT
PBS-LT
PBS-LT
0.1M HCl

prot# 5
antigen
+φ
empty beads
PBS-T
PBS-T
PBS-LT
PBS-LT
PBS-LT
0.1M HCl

vol
171µl lib + 19µl antigen
incubate 1hr RT
200 µl
190 µl
190 µl
190 µl
190 µl
190 µl
150 µl

Each round had two parts;
1) Interaction and elution of phages with the antigen
2) Amplification of the output
Library used was a tertiary phage library with a concentration of 1.0x1010 cfu/µl.

1) Interaction and elution of phages with the antigen
The whole process takes place in KingFisher plates
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- Incubation of the blocked library and antigens for an hour at room temperature
- Incubation of the mixture of library and antigen with the streptavidin magnetic beads
(Dynabeads, DYNAL) for 15 min at room temperature
- Elution with HCl for 3.5 min followed by immediate neutralization with 50 µl of 1.5 M
tris pH=8.8.
- 100 µl of the neutralized eluted phages, was used to infect 1 ml of DH5 F cells at
OD600=0.5 and left to incubate at 37ºC for 45 min in steady state.
- 5µl of the infected bacteria was plated on Ampicillin (0.1 mg/ml final)/glucose (3%
final) agar plates to give us an idea of the order of magnitude of the output.
- The remaining output was plated on a large Ampicillin/glucose agar plate
Both plates were incubated over night at 30ºC.
2) Amplification of the output
- Scrape off the cells from the large Ampicillin plate in 2 ml of 2xTy media
- Use 10µl of the resuspended cells to inoculate 10 ml of 2xTy (Amp/Glu) media and
incubated at 37º C to reach a density of OD600=0.5.
- Add 1.3 ml of helper phage to the bacteria and incubate standing for 45 min
- Centrifuge for 10 min at 3,700 rpm
- Resuspend cell pellet in 10 ml of 2xTy, Ampicillin, Kanamycin media
- Incubate over night at 30º C, 260 rpm.
- Centrifuge at 3,000rpm for 20 min and recover the supernatant containing phages
- Remove a 500 µl aliquot and use as input for the next selection round.
- PEG precipitate remaining phages (chapter 2: PEG precipitation of phages)
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Each selection was comprised of three rounds where the antigen concentration and the
washes were varied as shown in the table
antigen concentration
washes

1st round
0.6 µM
1 min

2nd round
0.06 µM
5 min

3rd round
6 nM
15 min

2.11 Immunotube selections:
Day 1:
To a 75x12 mm NUC immunotube (Maxisorp) add 10µg of antigen in 4ml of PBS.
Leave overnight to coat.
Day 2:
Start a 10 ml of DH5αFT culture in 2xTy/3%glucose/1x tetracycline (15µg/ml) (per
immunotube). 37°C, shaking
Wash tube 2-3 times with PBS (simply pour in and pour out again immediately)
Block by filling the tube to the brim with 2% milk in PBS (MPBS). Cover with parafilm.
37°C, rotating, 1-2 hrs
Pre-blocking the library: Make up 1013tu library phage to 4ml of 2% MPBS (2ml of 4%
MPBS, 1ml PBS, 1ml library phage). Room temperature (RT), 30min, rotating.
Wash immunotube 3 times with PBS (3xPBS)
Add the blocked library to blocked immunotube. 30min, RT, rotating and then 1.5hrs,
RT, standing.
Wash tube:
Round 1Æ 2x PBST (PBS with 0.1% Tween 20) then, 2x PBS.
Round 2Æ 10x PBST, then, 10x PBS.
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Round 3Æ 20x PBST, then, 20x PBS.
Elute phage with 1m of 1mg/ml trypsin freshly diluted in PBS. (add 900µl of PBS to the
100µl of trypsin (10mg/ml). 30 min, 37°C, standing.
Add 10µl of trypsin eluate t 10ml of DH5αFT at O.D. 0.5. 30 min, 37°C, standing.
Titrate 10µl on Amp/Tet/Glu plate:
For 2nd and 3rd round:
- Dilute 10µl into 90µl of media and plate on Amp/Tet/Glu plate
- Dilute 1µl into 90µl of media and plate on Amp/Tet/Glu plate
To be able to pick single colonies for ELISA.
Spin down the cells. 10min, 3700rpm.
Decant supernatant and resuspend the pellet on the little liquid left (~100µl).
Plate the cells on Amp/Tet/Glu. 37°C, overnight.
Day 3:
Scrape the lawn in approximately 2ml media with 15% glycerol.
Use 10µl to grow in 10ml of 2xTy Amp/Tet/Glu, till O.D. 0.5. 37°C, shaking.
Add 2x1010 of warm helper phage (at 37°C,) (200µl of 1x1011 stock) (20:1). 37°C,
30min, standing.
Streak on Amp/Glu, Kan/Glu, plates to check for helper phage infection (1µl). (library
plasmid has Amp resistance and Helper phage has Kan).
Spin down. 10min, 3000rpm.
Resuspend on Amp/Kan media (50ml). 30°C, overnight).
Coat a new immunotube for next selection round.
Day 4:
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Double PEG precipitate
Use 100µl for the next selection round.

2.12 PEG precipitation of phages
- Add 2 ml of pre-chilled 20% PEG+2.5M NaCl to each 10 ml supernatant sample
- Incubate on ice for 1hr to aid precipitation
- Centrifuge the phage precipitate at 3,000rpm for 30 min and discard supernatant
- Re-suspend each pellet in 1ml PBS
- Centrifuge the phage sample at 13,000 rpm for 15 min (to pellet bacterial pellet debris)
- Recover the 1 ml supernatant into a fresh microcentrifuge tube containing 167ul
PEG+NaCl
- Mix and incubate on ice to aid precipitation
- Centrifuge at 13,000 rpm for 10min (to pellet precipitated phage) and discard
supernatant
Briefly re-centrifuge (for 1 min) to recover traces of PEG
Re-suspend the phage pellet in 200ul of PBS and centrifuge at 13,000rpm for 5 min (to
pellet residual cell debris)
Transfer the phage containing supernatant to a fresh microcentrifuge tube and store at 4ºC

2.13 Protein expression:
2.13.1

Expression of proteins using IPTG as inductor

This protocol can be used to express recombinant proteins from plasmids with lac operon (e.g.
pDan5 and pRosa plasmids). The cell strains used in each case was different as the pRosa vectors,
being a derivative from pET281 vector, needed the presence of the T7 polymerase in order to start
expression. The presence of this polymerase is indicated in the genotype by DE3 and the strain
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used in this cases was either BL21(DE3)(gold) or BL21-pLYsS(DE3). In the case of pDAN5
vector the strains used were DH5αF’ or DH5αF’T. When using BL21-pLYsS(DE3) growth
temperature can be higher, 37°C, than when using BL21(DE3)(gold) as they are more tightly
regulated, the possibility of leak is lower and thus toxicity is lower.
Induction of scFvs from pRosa vectors in BL21-pLysS or BL21(gold) with 2xTy media:
Volume of media can vary. The flask should vary accordingly so it is always 5 times larger than
the volume of media.
-

The growth media will be 2xTy with 3% of glucose and 1x of Kan

-

inoculate the media using several colonies from over night plate grown at 37ºC

-

incubate at 30ºC shaking at 260 rpm until OD ~0.8

-

prepare induction media: same volume as earlier of 2xTy, 1x Kan and 250 µM IPTG

-

Spin down and resuspend the pellet in the induction media

-

Incubate over night at 25ºC and 260 rpm

-

Spin down and keep the pellet in the -80ºC freezer of proceed to extraction of the protein.

2.13.2

Expression of proteins using autoinducing media

As explained in paper:
Studier, F. W., Protein production by auto-induction in high density shaking cultures.
Protein Expr Purif 2005, 41, (1), 207-34.

2.14 Periplasmic extraction protocol
Buffers:
-5 mM MgSO4
- PPB Buffer
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2.14.1.1 -PPB buffer (for a final vol of 1L):
-50 mM tris-HCl (pH=7.6)
-25 ml of 2M tris pH=7.5
-1 mM EDTA
- 2 ml of 0.5 M EDTA
20 % Saccharose (sucrose)
- 20 g of dry sucrose
Filter sterilize with 0.2µm filter.
Note: This protocol can be scaled up or down depending on the amount of bacteria
working with. Some variations on the volume can be done in order to get more or less
concentrated extract.
1) Starting with a 50 ml culture of induced bacteria. Centrifuge culture at 4000 rpm, 10
min.at 4ºC.
3) Re-suspend pellet in 1.25 ml cold PPB buffer, transfer into micro centrifuge tubes and
incubate on ice for 20 min.
4) Spin at 14000 rpm for 7 min in cold and transfer the supernatant to a sterile tube.
5) Resuspend the bacterial pellet in 500 µl of 5 mM MgSO4 (or MgCl2). Incubate at RT
for 10 min. Spin at 10,000 rpm for 7 min. Combine the supernatants.
6) Spin combined supernatant at 14000 rpm for 7 min to remove small particles, and
transfer to a new tube.
Final volume 1750 µl of p.e.
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2.15 LSRII :
2.15.1

parameters:

Loader Settings
Flow rate = 0.5ul/sec
Sample volume = 25ul
Mixing Volume = 100ul
Mixing Speed = 250ul/min
Number of mixes = 5
Wash volume 800ul

Parameters
Filters voltage Log

A

H

FSC
SSC
FITC
APC-Cy7
APC-Cy7

Y
Y
Y
Y
Y

Y
Y
Y

313
177
650
381
266

Y
Y
Y
Y
Y

2.16 SV5 ELISA
Consumables:
-

Mouse immunoglobulins/AP (D0486, Dakocytomation)

-

SV5 antibody

-

NUNC Maxisorp™ plates (96 and 384 wells) (eBiosciences)

-

PBS (Fisher)

-

Tween-20 (SIGMA)

-

Neutravidin (Pierce)

-

Wonder block: skim milk, fish gelatin and BSA, all of them at 0.3% dissolved in
1x PBS.

-

NBT/BCIP, Pierce
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Volumes and concentrations:

antigen
washings
blocking agent
antibodies
ap-substrate

volume in plates
384 well 96 well
(µl)
(µl)
50
100
100
200
100
200
50
100
80
160

final
concentration amount/well
neutravidin
0.5-1 µg
antigen
0.1-1 µg
α-SV5
5 µg/ml
50-100 µl
α-mouse
5 µg/ml
50-100 µl

All the steps are done at room temperature with no shaking unless indicated.
1- Coat over night with neutravidin at 4º C. If coating the plate directly with the antigen,
start in step # 1.1 and skip steps #4 & 5
1.1- Coat with antigen over night at 4º C or 1 hr at 37º C (skip this step for
neutravidin coated plates)
2- Wash twice with PBS-LT (1xPBS with 0.01% tween-20)
3- Block with wonder block for 1 hr
4- Incubate plates with biotinylated antigen for 1 hour at 37ºC (skip this step for no
neutravidin coated plates).
5- Wash two times with PBS-LT
6- Add expressed scFvs and incubate for 1.5 hrs.
7- Wash two times with PBS-T and two more times with PBS-LT
8- Add anti-SV5 antibody and incubate for 1 hr
9- Wash three times with PBS-T and three more with PBS-LT
10- Add anti-mouse-ap and incubate for 1 hr
11- Wash three times with PBS-T and three more with PBS-LT
12- Develop the assay with alkano phosphatase susbstrate was used NBT/BCIP
13- Read absorbance at 405 nm using the SPECTRAfluor Plus spectrometer.
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Some modifications that sometimes were done to this procedure were:
-

Use of α-mouse-HRP as secondary antibody. The way to develop the assay is by
the use of 100µl of TMB-ELISA substrate (Pierce); the signal was quenched with
50 µl of 1M H2SO4. Readings were performed at 450 nm.

-

2.17 SDS polyacrylamide gel electrophoresis
Supplies:
-

NuPAGE™ 4-12% Bis-Tris gels, Invitrogen, with either 12 or 17 wells.

-

The gel apparatus was Novex Mini-cell, Invitrogen.

-

Power supply BioRad PowerPac HC or BioRad MODEL 200/2.0 Power Supply.

-

1x MES running buffer (20x buffer having the following composition 1M MES,
1M tris Base, 69.3mM SDS, 20.5mM EDTA (acid free).

-

4x denaturing loading dye (recipe at the en of the protocol)

Procedure:
Samples with 4x denaturing loading dye were boiled at 100ºC for 7 min, volume of
sample plus loading dye was usually around 20µl. The gel was pre-rinsed with distilled
water and placed in the gel apparatus, buffer compartments were then filled and comb
removed to uncover the wells. The samples were then loaded in gel.7µl of protein marker
used was (Precision-plus Kaleidoscope (BIORAD.)) Power supply was set to apply 200V
for 35 min. The gel was then taken out of the plastic case and rinsed with double distilled
water and developed by staining with gel code of silver. (Recipe follows)
Note: In case of the purification using affinity tags (Chapter 3, section 3.5). it was loaded
on the gel 10µl of eluted fraction with 5 µl of loading dye.
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2.17.1

10x protein loading dye (10 ml):

2 ml 1M Tris-HCL; pH 6.8
0.8 g SDS
4 ml 10% glycerol
0.4 ml 14.7 b-mercaptoethanol
1 ml 0.5M EDTA
8 mg Bromophenol Blue

2.17.2

Gel Code staining

Consumables and buffers:
•

Fix Buffer: 50% Methanol, 10% Acetic acid

•

Gel-Code stain (Pierce, cat# 24590)

To a polyacrilamide protein gel.
•

Rinse with nano-pure water; three times for 5 min each.

•

Incubate the gel in Fix Buffer for 10 min.

•

Re-hydrated gel in nano-pure water, three times for 5 min each. Not need to
shake.

•

Add Gel-code solution to cover the gel. Incubate for up to an hour.

•

Destain gel with large volume of nano pure water.

All the steps were done at room temperature with slow rotation. Stained gels were then
scanned.
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2.17.3

Silver staining

To a polyacrilamide protein gel.

Step

Solutions

Recipes

Operation

Time
2 x 15

1

Sol A

50% MeOH/ 7% AcOH/43% H2O

Fix

min

2

Sol B

50% MeOH/ 50% H2O

Incubate

10 min
2

3
4

Sol C (fresh)

5
6

Sol D

7

X

5

ddH2O

wash 2x

min

0.02% Sodium thiosulfate (Na2S2O3)

Sensitize

3 min

ddH2O

wash 2x

2 x 1 min

1.2% of Silver Nitrate (AgNO3) 1 N

Incubate

25 min

ddH2O

wash 2x

2 x 1 min

Develop

~ 10 min

10 min

3 % Sodium Carbonate (NaCO3)
8

Sol E (fresh)

0.05% of 37% HCOH (formaldehyde)
2 % Sol C
H2O

9

Sol F

5% AcOH/ 95%H2O

Stop

10

Sol G

1% AcOH/99%H2O

Store

2.17.4

Gel transference into membrane (blotting):

The SDS protein gel with the samples resolved on it was incubated for 10 min in 1x transfer
buffer (Invitrogen). The gel was transferred to 0.2µm nitrocellulose membrane (Protran BA83;
Schleicher & Schuell Bioscience). The gel was placed over the membrane and in between 6 layers
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of filter paper (BioRad) in the XCell II™ Blot Module (Invitrogen).The current was set depending
of the area of transference calculating the mA needed as 0.8x cm2 . The gel transfer was run for 50
min.

2.17.4.1 SV5 western
Proteins blotted in a membrane.
All the steps are done at room temperature shaking. The development is done with no
shaking.
The solutions are prepared in 1% fish gelatin (F.G.) in 1x PBS
•

1x anti-SV5 (1:1000)

•

1x anti-Mouse IgG-Alkaline Phosphatase (AP) (1:2000) (Dakocytomation)

Block the membrane for an hour with 4.5% fish gelatin in 1xPBS. Incubate with 1x antiSV5 for 1 hr. Wash for 10 min with PBS-T and for 10 more min with PBS. Incubate for 1
hr with 1x anti-Mouse-ap. Wash for 15 min with PBS-T and for 15 min with PBS.
Develop with 1 step NBT/BCIP substrate (Pierce).

2.18 Beads for affinity tags:
MBP
CBD
Strep-tag II

matrix
amylose resin
Chitin beads
Strep-Tactin® Sepharose

from
New England Biolabs
New England Biolabs
IBA

2.19 Tag purification; buffers and protocols:
Consumables:
-

Ni-NTA beads (BioRad)

-

Chitin beads (NEB)
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-

Strep- tactin agarose beads (IBA)

-

Amylose beads(NEB)

-

Micro Bio-spin Chromatography columns (Bio-Rad)

-

Chemicals from SIGMA and Fisher

Each set of beads was pre-washed twice with the corresponding washing buffer, spinning
at 5000rpm for 1 minute between washes.

2.19.1

Purification using Ni-NTA beads:

Add to the samples the same salts as in the wash buffer and in the same concentrations

2.19.1.1 Wash buffer:

Elution buffer:

1x PBS

1x PBS

0.5 M NaCl

0.5M NaCl

5 mM imidazole

0.5 M imidazole

2.19.1.1.1

Purification protocol:

- wash beads 2 times with 1 ml of wash buffer 1
- incubate sample and beads for 1 hour rotating at 4 ºC
- place beads in column and let sample flow by gravity
- wash with 3 ml of wash buffer
- elute with three fractions of 100µl of elution buffer.

2.19.2

Purification with Strep-Tactin Beads:

2.19.2.1 Washing buffers:
Wash buffer 1: PBS-T (1x PBS with 0.1% tween-20)
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Wash buffer 2: PBS-LT (1x PBS with 0.01% tween-20)
Wash buffer 3: 1x PBS

2.19.2.2 Elution Buffer:
2.5 mM desthiobiotin in 1xPBS. Use warm PBS to be able to dissolve the desthiobiotin.

2.19.2.2.1

Purification protocol:

- wash beads 2 times with 1 ml of wash buffer 1
- incubate sample and beads for 1 hour rotating at 4 ºC
- place beads in column and let sample flow by gravity
- wash with 3 ml of wash buffer 1
- wash with 3 ml of wash buffer 2
- wash with 1 ml of wash buffer 3
- elute in 3 fractions of 100µl of 2.5 mM desthiobiotin

2.19.3

Purification with chitin Beads:

2.19.3.1 Wash buffer 1: 10 mM phosphate buffer
-

10X Sodium Phosphate Buffer (100mM Sodium Phosphate pH7), 1L

-

500mls of 1M Dibasic Sodium Phosphate (Na2HPO4)Add 71g and make up to
500mls with dH20 500mls of 1M Monobasic Sodium Phosphate (NaH2PO4)

-

Add 69g and make up to 500mls with dH20

-

Add 50mls of 1M Dibasic Sodium Phosphate to 50mls of 1M Monobasic
Sodium Phosphate and make up to 1L with dH20.

1X Sodium Phosphate Buffer (10mM Sodium Phosphate pH7), 1L
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-

Add 100mls of 10X Sodium Phosphate Buffer to 900mls of dH20

2.19.3.2 Wash buffer 2: 10 mM phosphate buffer + 1M NaCl
1X Sodium Phosphate Buffer + 1M NaCl (10mM Sodium Phosphate pH7), 500ml
-

50ml of 10X Sodium Phosphate Buffer

-

29.2g of NaCl

-

Make up to 500ml with dH20

2.19.3.3 Wash buffer 3: 0.1 M acetic acid
[stock]=17.4N=17.4M
-

2.19.3.3.1

11.4 ul conc acetic acid + H2O till 20 ml

Wash buffer 4: 1x PBS

Purification protocol:

-

wash beads with 2 ml of wash buffer 1

-

incubate sample and beads for 1 hour rotating at 4 ºC

-

place beads in column and let sample flow by gravity

-

wash beads 2 ml of wash buffer 1

-

wash beads 2 ml of wash buffer 2

-

wash beads 2 ml of wash buffer 3

-

wash beads 3 ml of wash buffer 4

-

add 100 µl of loading dye to the beads and remove them out of the column by spinning

2.19.4

Purification with Amylose beads:

Add to the sample the same salts in the same concentrations as in the wash buffer.
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2.19.4.1 Wash buffer
20 mM Tris-HC (pH=7.4)

Elution buffer
wash buffer + 10 mM maltose

0.2 M NaCl
10 mM β-mercaptoethanol (added right before use)
1 mM EDTA

2.19.4.1.1

Purification protocol:

- wash beads 2 times with 1 ml of wash buffer 1
- incubate sample and beads for 1 hour rotating at 4 ºC
- place beads in column and let sample flow by gravity
- wash the beads with 3 ml of wash buffer
- elute with 3 fractions of elution buffer (100 µl)

2.19.5

Biological LP purification:

Used for Ni-NTA purification of His tagged proteins:
Consumables:
Econo-columns (BioRad)
Ni-NTA beads (BIORAD); volume used as indicated by manufacturer.
Buffers specific for Ni purification (see section buffers)
Procedure:
The flow will always be kept at 1ml/min
Salts are added to the sample in such a way the final concentration will be the same as in the
washing buffer. The sample will then beintroduced on to the column. Washing will be performed
until the absorbance (280 nm) reaches the base line and at that point elution will be started, being
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a gradient of elution buffer form 0-100% in 35 min. Elution fractions will be collected by the autosampler in 1.5 ml microcentrifuge tubes, being each fraction of 500µl.

2.19.6

SV5 purification using protein A tips (Phynexus):

Consumables:
Protein A tips (Phynexus, PTR 92-05-01)
PhyTip ME 200 Purification System (Phynexus, PHR 12-020-00)
anti-SV5 antibody
Buffers from the protein A purification kit: purification and enrichment
PCR plates
PBS-T
PBS-LT

Procedure:
Each sample and washing buffer was placed in a well of a PCR plate. Volume of washing buffer
was 200 µl in each well. Volume of elution buffer was 40 µl. First well contained the

-SV5

mixture to be captured by the protein A tips.
Single purification with a-SV5 was performed by running the step #4 of capture over the initial
sample (mixture of scFvs and cell extract with antigens). Double purification was done by running
this step over each of the strep-tactin eluted fractions.
The programs used are the ones designed by the manufacturer for the 200 protein A tips. For the
elution the capture program was modified to aspirate 30 µl.
protocol “200+protein A”
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capture: 200+ default proA capture
wash 1: 200+ default proA Wash 1
wash 2: 200+ default proA Wash 2
elution: 200+ default proA enrichment

Prepare the anti-SV5 sample to coat the tips:
2 µl of anti-SV5 (5µg/µl) + 128 µl 1xPBS
40 µl of 5x capture buffer (PBS)
30 µl deionized water

1- 2x “capture: 200+ default proA capture “- on the a-SV5 sample
2- 1x wash 1: 200+ default proA Wash 1- purification buffer
3- 1x wash 2: 200+ default proA Wash 2- purification buffer
4- 2x “capture: 200+ default proA capture “- on each of the strep-tactin eluted fractions
5- 1x wash 1: 200+ default proA Wash 1- PBS-T
6- 1x wash 2: 200+ default proA Wash 2- PBS-T
7- 1x wash 1: 200+ default proA Wash 1- PBS-LT
8- 1x wash 2: 200+ default proA Wash 2- PBS-LT
9- 3x elution: 200+ default proA enrichment
10- Add 5 µl of neutralization buffer
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2.20 Preparation of Shewanella oneidensis MR-1 cell pellet
(By Shu-mei W. Li on behalf of Dr. James K. Fredrickson)
Culture medium:
Bacto tryptic soy broth w/o dextrose (TSB) (Ref #286220, Becton, Dickson and
Company, Sparks, MD)
Pre-culture:
•

10 mL TSB, inoculate with 0.1 mL cryopreserved material of S. oneidensis MR-1
(stored at -80 °C freezer).

•

Incubation: 30 °C, 150 rpm gyratory shaking, overnight (18-20 h)

Culture:
•

500 mL TSB (in a 1000 mL size flask) inoculate with 5.0 mL pre-culture

•

Incubation: 30 °C, 150 rpm gyratory shaking, overnight (18-20 h)

Harvesting:
•

5,000 g x 10 min at 4 °C, decant supernatant, and store the pellet at -80 °C until
use.

•

Optional: re-suspend pellet with suitable volume of phosphate-buffered-saline
(PBS)* and centrifuged again. Decant supernatant and store the pellet at -80 °C
until use.

*Phosphate-Buffered-Saline (PBS): per liter
Na2HPO4 .7H2O

2.22 g

NaH2PO4 .H2O

0.223 g

NaCl

8.5 g

pH to 7.0
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2.21 Kcoil-Alexa488 synthesis
2.21.1

K coil sequence:

KVSALKEKVSALKEKVSALKEKVSALKEKVSALKEC

2.21.2

Synthesis:

Peptide was synthesized on an ABI 433A synthesizer using standard FastMoc Chemistry
in 0.25 mmol scale and double coupling of all residues. Reagents, solvents and
aminoacids were purchased from ABI, Fisher, Aldrich and NovaBiochem; all in in
synthesis grade. The resin was a Fmoc Cys Cl-trityl resin at 0.4 mmol/g loading from
ACT.

2.21.3

Deprotection/purification:

1. Add 10 mL of a solution of 92% TFA (sequencing grade), water 5% and 3%
Triisopropylsilane to 1 g resin. Incubate the resin for 8 h at rt on an orbital shaker under
Argon.
2. Precipitate peptide into 25 mL ice cold ether
3. Centrifuge, discard supernatant ether, then add fresh ether, re-suspend and centrifuge repeat his wash step 3 times.
4. Dry peptide under vacuum.
5. Redissolve in water with 0.1% TFA
6. HPLC purification of the peptide on a semi preparative Waters 600 system using a
Waters Symmetry column C18, 300 A (this is Angstrom), 7 µm, 19x150 mm at 20
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mL/min running a gradient from 92 % ACN/8 % H2O/0.1% TFA to 50% ACN/ 50%
H2O/0.1% TFA with a linear gradient in 12 min (rt 10.42).
7. Remove the ACN on a rotary evaporator and freeze dry the peptide on a lyophilizer.
Peptide when stored under argon can be used directly for derivatization of the Cys thiol.

2.21.4

Regeneration of the thiol after extended storage:

Using ReduceImm columns (Pierce/ immobilized and activated DTT on agarose)
samples for direct attachment of a thiol reactive dye can be prepared following the
manufacturer's protocol.

2.21.5

Attachment of the Alexa fluor:

Label the reduced peptide (from HPLC purification/ or from RedImm) with Alexa Fluor
488 (C5 maleimide). Ratio Alexa: peptide of 1:2 at pH 7.8 (PBS or RedImm buffer).
Purify the Alexa labeled peptide from unreacted Alexa fluor and excess peptide by gel
filtation (Bio-Gel P-6)
Larger peptide quantities were labeled as described above but purified on a semi
preparative Waters 600 system using a Waters Symmetry column C18, 300 Ǻ, 7 µm,
19x150 mm at 20 mL/min running a gradient from 94 % ACN/6 % H2O/0.1% TFA to
60% ACN/ 40% H2O/0.1% TFA with a step gradient (5) in 15 min (rt 17 min).

2.21.6

Peptide identification:

Peptides were identified on a Thermo LCQ ESI mass spectrometer in the positive mode
with 0.1% Formic acid / H2O and showed peaks at M+2 and higher ionization. The
peptides show a high portion of Na and K ion peaks in the ESI which are often observed
as counterions for Alexa fluorophores.
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1

Studier, F. W.; Moffatt, B. A., Use of bacteriophage T7 RNA polymerase to
direct selective high-level expression of cloned genes. J Mol Biol 1986, 189, (1),
113-30.
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Chapter 3. Vector construction and testing
3.1 Introduction
This chapter describes the construction of a set of vectors, pRosa, and demonstrates
their functionality. The aim of the thesis is to develop an alternate method for
immunoprecipitation of protein complexes. This method is based on the use of single
chain antibodies (scFvs) to interact with the target protein and pull down the protein
complexes formed.
The pRosa series of vectors were constructed to allow the directional cloning of
scFvs selected from a pDAN5 library selection1. These multifunctional expression
vectors provided the possibility of introduction of tags to be expressed as single chain
fusions. A set of affinity tags, CBP (Calmodulin binding protein), GST (Glutathione-Stransferase), strep tagII, CBD (Chitin Binding Domain) and MBP (Maltose Binding
Protein), were chosen and studied as fusions to the amino terminus of the scFv. These
tags were introduced to be used as purification handles of protein complexes bound to the
scFvs.
ScFv-tag fusions were checked for expression and interaction with the antigen, with
the conclusion that the presence of strep tag II, CBD and MBP do not have a negative
effect on either. Purification experiments demonstrated the use of the tags as purification
handles however strep tagII was the one selected for immunoprecipitation experiments
due to the mild washes and elution needed.
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3.2 Amplification of affinity tags:
The tags used in this study include the Strep tagII (strep), calmodulin binding
protein (CBP), chitin binding domain (CBD), glutathione-S-transferase (GST) and
maltose binding protein (MBP). These tags will be labeled “immunoprecipitation tags”
(I.P. tags) during this study to differentiate them from other tags already present in the
vectors.
The tags were cloned by PCR using primers containing specific restriction enzyme (RE)
sites and different sources as templates.
The destination vector was designed with the flexibility of being able to clone
tags at either the amino (N) or carboxy (C) termini of the single chain. However, the
studies were only completed with tags fused to the N terminus.
Primers were designed to introduce SfiI and AgeI restriction sites flanking the
tags for cloning at the amino terminus of the scFv. The primers were also designed to
include an additional non-encoding 33bp sequence to prevent steric hinderence at the
protein level, due to the location of the N terminus at the antigen interaction site of the
scFv. The genes encoding the tags MBP, GST, CBD, were amplified from the
commercial vectors (Refer to
1). In contrast, the genes encoding the tags StrepII and CBP were created by
linker annealing, due to their small sizes (91 and 142 bp respectively).
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Origin

from

Primers
Primers
PTYB1
PET-42
Pmal-p2x

Primers
Primers
NEB, Beverly, Mass
EMD biosciences
NEB, Beverly, Mass

TAG

R.S. (5)

flag
Strep tag II
CBP (1)
Chitin (2)
GST (3)
MBP (4)

SfiI/AgeI
SfiI/AgeI
SfiI/AgeI
SfiI/AgeI
SfiI/AgeI
SfiI/AgeI

(1) Calmodulin binding protein

SIZE(bp) expressed protein
(kD)
21
31.8
91
33
142
35
222
37.5
723
57.4
1167
72.2

(5) Restriction sites

(2) Chitin binding domain
(3) Glutathione-S-transferase
(4) maltose binding protein

Table 3-1: Cloned tags information. Including a scFv of 31 kD.

25 bp

Strep
CBP tag II

Chitin
Binding
domain

φx-HaeIII

GST

HindIII+ MBP
φx-HaeIII

200
125

872
603

1353
1078

Figure 3-1. Amplification of the tags by pcr; CBP, Strep-tag II, CBD, GST and MBP

The PCR reaction and linker annealing amplification method is described in
chapter 2: PCR. PCR amplification produced DNA fragments of the expected size in all
cases (refer to Table 3-1). Following gel excision, the DNA was extracted (QIAGEN gel
extraction kit), digested with restriction enzymes AgeI and SfiI, and purified in
preparation for subsequent cloning steps. The prepared DNA was then stored at -20° C.
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3.3 Creation of expression vector for scFv-tag fusions
(pRosa6):
The expression vector, pRosa6, was created for compatible sub-cloning of DNA
encoding single chain antibodies originating from the pDAN5 library. In addition, the
vector was designed to include one or more affinity tags to aid protein solubility,
expression and purification.
The commercial vector pET28b2 (Novagen) was modified by introducing restriction
enzyme sites to allow directional cloning of genes encoding both the tags and single
chain antibodies. The expression vector, pRosa6, was created by sequential modifications
of the display vector, pDAN5, and subsequent amalgamation with pET28. A theoretical
scheme of the cloning is shown (Refer to Figure 3-2). All the preliminary experiments
were performed using 3A scFv as a model single chain. 3A is a scFv that recognizes the
SNV-N (sin nombre virus nucleocapsid) protein3.
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- Introduction of restrictions sites (R.S.) SfiI, AgeI, NcoI and a flag gene.
HindIII

BssHII

NheI

PelB

PDan 5
PelB

PDan 6
NcoI

flag

SfiI

*

ScaI

NotI

EcoRI

scFv

SV5

His

g3

scFv

SV5

His

g3

AgeI

*flag epitope will remain attached to the scFv after cleavage of the pel b leader in the periplasmic membrane
-Cloning into the pET-28 vector

NcoI/EcoRI insert from pDan6

PelB

NcoI EcoRI

NcoI

scFv

flag

pDan 6 insert
SfiI

AgeI

BssHII

SV5

His

NheI

g3
NotI

EcoRI

pET-28b

Kan

lacl

T7

* the flag gene was used with the idea of substituting it later with other tags

T7 promoter
PelB

Flag gene

LacI

scFv
SV5 tag
His6

pRosa6

g3p

7452 bp

His tag

kan gene

Figure 3-2. Schematic of the cloning process to engineer pRosa6.
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3.3.1 Cloning of pDAN6:
The first step in the creation of pRosa6 was the introduction of a FLAG tag gene and
restriction enzyme sites SfiI, AgeI and NcoI into the pDAN5 vector.
This gene, flanked by AgeI and SfiI restriction sites, was introduced upstream of the
single chain with the plan of substituting it later for different tags. An NcoI restriction site
was also introduced for future cloning steps. This created the pDAN6 vector.
The sequence encoding the FLAG tag was PCR amplified from the pDAN11 vector4
using the primers pelBNcoI/pelBsfiI. Following PCR amplification (Chapter 2, PCR), the
143 bp DNA product was digested with BssHII and HindIII restriction enzymes and was
cloned directionally into BssHII/HindIII digested pDAN5 vector.
Following ligation and transformation, the DNA produced from six transformants was
digested with a range of restriction enzymes to obtain a fingerprint for each clone (Refer
to Figure 3-3)
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HindIII

NcoI
primers

SfiI
pelBsfiI

pelbNcoI

pDAN5

AgeI BssHII
flag

PelB

PelB

PCR on pDAN11

BssHII/HindIII

digestion

Ligation
pDAN6

pDAN 6
fragment

HindIII NcoI SfiI AgeI BssHII
PelB
flag
scFv

NheI

NheI

ScaI
SV5

His

EcoRI

NotI
g3

NheI + BssHII
NheI + AgeI
NheI + SfiI
NheI + NcoI
NheI + HindIII

Figure 3-3. Schematic of the creation of pRosa6 and fingerprint
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3.3.2 Cloning of pRosa6:
The expression vector pRosa6, was constructed by directionally cloning the 2.1 kbp
NcoI/EcoRI fragment from pDAN6 into NcoI/EcoRI digested pET28b (Refer to Figure
3-4). To construct the pRosa6-3A vector, the pDAN6 vector was digested with NcoI and
EcoRI restriction enzymes (R.E.). The 2.1 Kbp fragment was recovered and sub-cloned
into NcoI/EcoRI restricted pET-28b to create pRosa6. The pRosa6 vector was
characterized by fingerprinting with a panel of restriction enzymes as shown in Figure
3-4).
HindIII+
φx-HaeIII

6557
4361

5.4 kb

2322
2027

2.1 kb

(2)

(1)

Figure 3-4. Purified fragments of pET-28 (1) and pDAN6 (2) vectors, digested with EcoRI and NcoI.
Ligation of both fragments produce pRosa6
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Colony

HindIII+
φx-HaeIII

Digestion

1

2

3

U N/E E/C U N/E E/C U N/E E/C

4
U N/E E/C

4361
2322
2027
1353

603

Figure 3-5. Fingerprint of 4 colonies from pRosa6 ligation. Undigested (U), NcoI and EcoRI digestion
(N/E), EcoRI and ClaI digestion (E/C)

Digestion with NcoI/EcoRI (N/E), produced two fragments of 2187 and 5265 bp.
Digestion with EcoRI and ClaI (E/C), produced fragments of 366, 1446 and 5640 bp.
Restriction enzyme analysis demonstrated that all cloned features of pRosa6 were
present. Sequence analysis confirmed the DNA sequences were correct and in frame.

3.4 Cloning of the Tags into pRosa6:
A panel of expression vectors was produced by interchanging the Flag tag gene of
PRosa6 with the I.P. tags described in section 3.2. The DNA fragments encoding the tags
(Refer to section 3.2), previously digested with SfiI and AgeI restriction enzymes, were
directionally ligated into the 7.4 kb AgeI/SfiI digested pRosa6. The resulting clones were
checked for the presence of cloned DNA fragments via restriction enzyme digestion with
NcoI and AgeI. The expected DNA fragments are described in Table 3-2 and the
digestions shown in Table 3-2.
pRosa6-scFv-Strep
pRosa6-scFv-CBP
pRosa6-scFv-Chit
pRosa6-scFv-GST
pRosa6-scFv-MBP

NcoI/AgeI fragments (bp)
7369, 131
7369, 185
7369, 260
7369, 761
7369, 1032, 173

Table 3-2: Fragments after NcoI and AgeI digestion
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pRosa6-scFv-strep
25 bp
ladder

25 bp
ladder

300

125

131

pRosa6-scFv-GST

pRosa6-scFv-CBP
pRosa6-scFv-chitin

260
185

pRosa6-scFv-MBP
HindIII+
φx-HaeIII

HindIII+
φx-HaeIII

2322
2027
1353
1078

125
872

872

1032

761

603

Figure 3-6. Digestion of pRosa6-scFv-CBP, pRosa6-scFv -chitin, pRosa6-scFv -GST, pRosa6-scFv MBP and pRosa6-scFv -strep with NcoI and AgeI RE.

ELISA (Enzyme Linked Immunosorbant Assay) was used to demonstrate that the
presence of tags did not affect the ability of the single chain to bind its antigen.
Expression of the right size single chain fused to tags was checked by Western blot.
When examined by western blotting (Refer to Figure 3-7) all the tags, except GST gave
bands of the appropriate size. However, in addition to GST, CBP also gave very low
expression levels (Refer to Figure 3-7), and as a result, further work with these two tags
was discontinued. All tags gave two additional prominent bands at 17-19 kD. Similar
bands have been seen with scFv without fusion tags, and are thought to represent the VH
chain fused to the SV5 tag.
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SV5 ELISA on scFvs-tag proteins expressed
from pRosa6 vectors

kD
3.5

150
3

Abs @ 450 nm

100
75

50

37
25
20
15

2.5

SNVN
ADH
Myo
Ubq

2
1.5
1
0.5
0

3A

10

strep

CBD

CBP

GST

MBP

3A-MBP

3A-CBP

3A-GST

3A-CBD

3A-strep
3A

scFv-tag fusions

Figure 3-7. Expression of pRosa6 vectors with different tags. Samples analyzed by SV5 Western blot
and ELISA. Refer to Table 1 for sizes

ScFv fusions to Strep tagII, CBD and MBP expressed from pRosa6 vectors gave good
ELISA signals comparable to the ones obtained from the non tagged vector. They also
showed specificity for the selected antigen. CBD and GST fusions gave little or no signal
corresponding to the low expression levels found on the Western blot.
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3.5 Evolution of the pRosa6 vector:
The expression vector pRosa6 underwent different modifications in order to make it more
versatile and to improve the quality of the final expressed protein. A scheme provides
information of the modifications and the engineered vectors.
T7 promoter
PelB

Flag gene

LacI

Bss HII (386)

scFv

Bss HII (6510)

SV5 tag
His6

NotI (1220)

pRosa6

g3p

7452 bp

Removal of a BssHII R.S. in the LacI gene
NotI (2509)

T7 promoter
PelB

kan gene

Flag gene
Bss HII (386)

LacI mod

scFv
SV5 tag
His6
NotII (1220)
Not

pRosa7
7453 bp

g3p

NotII (2509)
Not

T7 promoter
PelB

kan gene

Flag gene

Bss HII (386)

LacI mod

scFv

Removal of the gene 3
SV5 tag
His6

NotII (1220)
Not

pRosa8
6164 bp

kan gene

Figure 3-8. Evolution of the pRosa vectors

71

3.6 Creation of pRosa 7:
In order to exchange single chains, a new modification needed to be done to the
tagged expression vector pRosa6. The strategy for cloning scFvs into pRosa6 involved
digestion with NheI and BssHII restriction enzymes. However, a second BssHII site
present in the LacI gene, needed to be removed before cloning was possible (Refer to
Figure 3-8). Mutagenesis was the method chosen to remove it, and was performed using
the GeneTailor™ Site-Directed Mutagenesis System (Invitrogen). The primers, LacI and
LacImut (Refer to chapter 2: Primers), were designed to introduce a base pair mutation at
the LacI BssHII site so that the restriction site would disappear whilst not changing the
amino acid composition.

BssHII
~~~~~~~~
GGA CTC GGT AAT GGC GCG CAT
CCT GAG CCA TTA CCG CGC GTA
Ser Glu Thr Ile Ala Arg Met

Mutated gene

GGA CTC GGT AAT GGC ACG CAT
CCT GAG CCA TTA CCG TGC GTA
Ser Glu Thr Ile Ala Arg Met

Figure 3-9. Schematic of the mutation introduced to remove the BssHII site from the lacI gene.

The mutated clones were checked by digestion of the DNA with BssHII. The
presence of two BssHII restriction sites in pRosa6 produced two fragments of 6124 and
1328 bp while mutated vector is linearized. The new vector with mutated LacI gene was
named pRosa7.
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φx-HaeIII

a6
os ol
p R o n tr
c

os
pR

a7

1328

1353
1078
872
603

Figure 3-10. BssHII digestion of pRosa7 and pRosa6

All the tags were then transferred from pRosa6 into pRosa7 by two different
cloning strategies.

XbaI

NcoI

SfiI AgeI BssHII
PelB
tag
scFv

tag

XbaI

NheI

EcoRI

NotI
SV5

g3

His

strep-tag II or CBD

NcoI BssHII
AgeI BssHII
NcoI SfiI
PelB
MBP
scFv

NheI

EcoRI

NotI
SV5

His

g3

Figure 3-11. Diagram showing the extra R.S. found in the DNA encoding the MBP tag
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DNA encoding the Strep-tag II and the CBD were cloned into pRosa7 vector by digestion
of the correspondent pRosa6-tag plasmids with NcoI and EcoRI restriction enzymes
(Refer to Figure 3-11). The 2364 bp CBD fragment and 2235 bp strep tag NcoI/EcoRI
fragments were cloned into NcoI/EcoRI digested pRosa7.
Due to the presence of an NcoI site inside of the gene encoding the MBP tag, a
different cloning strategy was used. The 3348 bp XbaI/EcoRI fragment, containing the
MBP gene, was cloned into XbaI/EcoRI digested pRosa7 (Refer to Figure 3-11).
The resulting clones were characterized by restriction enzyme digestion, as shown in
figures 3-12 and 3-13.
pRosa7-scFv-CBD
λ-HindIII

6557

2322

N/E

pRosa7-scFv-strep
λ-HindIII

B

N/E

B

6557

2322

Figure 3-12. pRosa7-scFv-chitin and pRosa7-scFv-strep vectors checked by digestion with
NcoI/EcoRI (N/E) and with BssHII (B)
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λ-HindIII

X/E

6557
2322

Figure 3-13. pRosa7-scFv-MBP vector checked by digestion with XbaI/EcoRI (X/E)

With the pRosa7 vectors engineered to contain three different I.P. tags, a new
mutation had to be done to the pRosa7-scFv-MBP vector in order to be able to switch
single chains using BssHII and NheI restriction sites The pRosa7-scFv-MBP vector gene
contained a second BssHII restriction site within the MBP gene that interfered with the
cloning plan of new single chains (Refer to Figure 3-11). This site was removed by
mutagenesis using the GeneTailor™ Site-Directed Mutagenesis System (Invitrogen),
with the primers MBPmutg5 and MBPmutgnew3 (Chapter2, primers)

BssHII
~~~~~~~~
GGT AAG AGC GCG CTG ATG TTC AAC CTG
CCA TTC TCG CGC GAC TAC AAG TTG GAC
Gly Lys Ser Ala Leu Met Phe Asp Leu

Mutated gene

GGT AAG AGC GCT CTG ATG TTC AAC CTG
CCA TTC TCG CGA GAC TAC AAG TTG GAC
Gly Lys Ser Ala Leu Met Phe Asp Leu

Figure 3-14. Mutagenesis on the MBP gene to remove the BssHII restriction site
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The DNA of the mutagenized clones was checked by restriction enzyme digestion
with BssHII. The non-mutated, containing two BssHII sites produced a fragment of 705
bp while the mutated ones, containing only one BssHII site, linearized (Refer to Figure
3-15).
mut)
φx-HaeIII
-MBP (
P
7-scFv
Fv-MB
c
-s
pRosa
7
a
pRos

872
603

705

Figure 3-15. BssHII digestion in mutated pRosa7-scFv-MBP (mut), and non mutated pRosa7-scFvMBP

3.6.1 Cloning of scFvs into the pRosa7 vector:
Three different single chains recognizing three different targets were used to
check the influence of the tags in the new expression vector D1.35, 4M5.3 6, and G4
(selected against TB protein RV2607, Refer to Chapter 4).
scFvs
D1.3
G4
4M5.3

Antigen
Lysozyme
RV2607 (1)
Fluorescein

from
mouse monoclonal
human from scFv library
mouse monoclonal and yeast display

(1) TB protein
Table 3-3: Single chains information

76

The 728 and 770bp BssHII/NheI fragments corresponding to the D1.3 and G4
single chain genes respectively, were sub-cloned from pDAN5 into the BssHII/NheI
digested pRosa7 vectors. In contrast, the single chain 4M5.3 was PCR amplified from
pDAN114 using Fwdantifluo and Revantifluo primers (Chapter 2: Primers). The PCR
product was then digested with BssHII and XbaI restriction enzymesand the resulting 770
bp fragment was cloned into the BssHII/NheI digested pRosa7 vectors (digestion with
XbaI and NheI restriction enzymes produces fragments with compatible overhangs).
λ-HindIII

2027

G4

4M5.3

D1.3

564

Figure 3-16. D.13 and G4 single chains digested with NheI and BssHII R.E; α-FITC single chain
digested with XbaI and NheI R.E

Each DNA clone was sequenced with the primers pDpH5’ and pDpH3’, and in
the case of the plasmids with MBP with also the MBP5 primer.The protein produced by
each pRosa7-scFv-tag clone, was expressed. The proteins recovered within the
periplasmic extract were analyzed by ELISA to determine interaction with the
appropriate antigen (Refer to Figure 3-17). The expressed proteins were also analyzed by
Western Blot analysis, to check the size and stability of the proteins.
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SV5 Western Blot
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PRosa7-4M5.3-MBP

PRosa7-4M5.3

PRosa7-4M5.3-strp

0.2
0

SV5 Western Blot
1)
128 kD

Abs @450 nm

85 kD

32.1kD

PRosa7- G4-strp

PRosa7- G4-CBD
PRosa7- G4-MBP

pDAN5-G4

PRosa7- G4

pDAN5-G4

18.3kD

pRosa7pRosa74M5.3 -strep 4M5.3 -CBD

pRosa74M5.3 -MBP
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2)

41.7 kD

pRosa74M5.3

1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0

RV2607
myoglobin

pDAN5- pDAN5- pRosa7- pRosa7G4(25C) G4(30C) G4
G4 -strep

pRosa7- pRosa7G4 -CBD G4 -MBP

Figure 3-17. SV5 western and ELISA assay on the tagged single chains D1.3, 4M5.3 and G4
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Western Blot analysis demonstrated that all scFv-tag fusions produced protein of the
expected size; and ELISA data confirmed that the protein interactions between D1.3,
4M5.3 and G4 and their respective antigens, lysozyme, fluorescein (FITC) and RV2607
was not affected by the presence of either strep tag II, CBD or MBP tag.

3.4.1 Creation of pRosa8:
PRosa8 was created by removing gene 3 from pRosa7 (Refer to Figure 3-8). Gene 3
encodes g3p, a phage coat protein that is used for the display of proteins (antibodies) on
the surface of bacteriophage. The gene was cloned into the expression tagged vectors
(pRosa) with the thought of being exchanged by tags to be cloned downstream of the
single chain. The expression of the gene 3 fused to a protein is known to be involved in
bacterial toxicity.78. Gene3 is preceded by an Amber stop codon which should stop the
translation of the gene using the appropriate cell strain (e.g.: BL21(DE3)). However as
basal expression may occur, it was removed as its presence was not required for the
purpose of the studies.
The pRosa7 vectors were digested with NotI, dropping the fragment of 1289 bp
corresponding to the gene. The bigger fragment, in each case, was re-ligated creating the
pRosa8 plasmid. The resulting DNA was checked by restriction enzyme digestion. Each
DNA clone was sequenced with T7prom and T7term primers and in the case of the
plasmids with MBP, the MBP5 primer was also used to check that the DNA encoding
gene3 was removed and all the vector features were in frame. To demonstrate that the
removal of gene3 protein did not compromise the antigen interaction, ELISA was
performed in D1.3 pRosa8 clones.
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SV5 ELISA on pRosa8-D1.3-tag vectors

Abs at 405 nm

3.5
3
2.5
2

lysozyme
myoglobin

1.5
1
0.5
0
D1.3

D1.3-strep

D1.3-CBD

D1.3-MBP

clones

Figure 3-18. ELISA assay in D1.3-tag fusions expressed from pRosa8 vectors

ELISA results indicate that the removal of the gene didn’t affect the antigen/antibody
interaction.

3.5 Functionality of the Tags:
The functionality of each MBP, Strep-tag II and CBD tag was studied by interaction
with appropriate bead matrices as G4-tag fusions (G4 is a scFv selected against TB
protein RV2607, Refer to Chapter 4, section 4.2). Each G4-tag fusion was at the same
time purified using Ni- NTA chromatography utilizing the C-terminus His tag as a
control of purification.
The amount of each matrix to use (Chapter2: beads for affinity tags) was determined by
the one with the highest binding capacity (Ni-NTA). 25µl of Ni-NTA matrix was used
and the corresponding volume to work with the same capacity of the chitin beads, strep
Tactin and amylose beads (Refer to Table 3-4). All the beads were in slurry of 50:50
resin: buffer.
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Bead capacity
beads for
~0.25 mg prot

slurry

Ni- NTA beads

0.5- 1 mg prot/ 100 µl
resin

25 µl beads

50 µl

Chitin

2 mg prot / 1ml bead

125 µl beads

250 µl

Amylose

3 mg prot / 1ml bead

83.5 µl beads

167 µl

Strep-tactin

3 mg prot / 1ml bead

83.5 µl beads

167 µl

Table 3-4: bead capacity and amounts used for the experiments.

The protein produced by each G4-tag clone was expressed (Chapter 2: protein
expression). The expressed protein, were recovered from the periplasmic extract, as
described in chapter 2. Each construct contained either the strep tag II, MBP or CBD tag
at the N terminus of the G4 scFv. Hexa-Histidine (His tag) and SV5 tags were also
located at the C terminus of the scFv and are used routinely for purification and detection.

His
tag
H
H
H

H
H

SV5
tag

scFv

H

I.P.
tag

Figure 3-19. schematic of the expressed protein-tag fusions
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The tagged proteins were purified against their corresponding matrices, and in addition
were analyzed against a non-specific matrix used as negative control of purification.
scFv-tag
G4-flag
G4-Strep

G4-CBD

G4-MBP

Beads
Ni-NTA
Chitin
Ni-NTA
Strep-tactin
Amylose
Ni-NTA
Chitin
Amylose
Ni-NTA
Amylose
Strep-tactin

expected interaction
+
+
+
+
+
+
+
-

Table 3-5: Fusions of G4 to tags and beads used to compare purifications and expected interaction
with the matrices.

scFv

I.P. tag (strep tag II, CBD or MBP)
His tag (for routine purifications)

Ni beads
specific beads
un-specific beads
washes

elute beads

what I’m hoping for
SDS PAGE
Figure 3-20. Schematic of the experiment designed to check for the affinity and specificity of the tags

The retained protein was eluted from the matrix using specific elution buffer in
each case except for the CBD tag (Chapter 2: Tag purification; buffers and protocols).
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The chitin binding domain could not be eluted from the chitin beads as the CBD protein
lacks a cleavage site. In this case, the CBD fusion protein was removed from the beads by
boiling9.
Three fractions of 700µl of periplasmic extract (1/10th of the p.e. derived from
60ml of culture) from each G4-tag fusion, were used for independent purifications. G4tag fusions were first incubated with the washed beads and then placed into an empty
column (BioRad) and allowed to settle by gravity, this first flow sample was kept for
analysis (Refer to chapter 2: Tag purifications; buffers and protocols). Each column was
washed with the specific washes designed for each type of beads. All the washes were
collected, and 2µl of each spotted in two nitrocellulose membranes. The first membrane
was stained using MemCode Reversible Protein Stain kit (Pierce). The second was
developed as a Western Blot (Chapter2: SV5 western). This was done to determine if the
washes were enough to remove un-bound material using α-SV5 antibody to detect the
presence of SV5 fused protein. The protein staining assay and the Western Blot
determined that the washes were enough to remove the non-specific material. Each
column (except the one containing the chitin matrix) was treated with the specific buffer
(chapter 2: tag purification; buffers and protocols) to elute the captured proteins from the
matrix. The eluted fractions were collected for analysis. Each sample produced in the
assay (including initial, flow through, wash and elution) was analyzed by protein staining
with Memcode and Western Blot analysis. The G4-CBD tag fusion protein was eluted
from the column by boiling in 100µl of 4x loading dye at 100ºC for 15min, 15µl were
used to run in gel.

83

amylose beads
250
150
100
75
50

250
150
100
75
50

37
25
20

37
25
20

E1
beads

tr p

beads
I
FT
G4
-s

in

I
FT
E1
hit

Strep-tactin

chitin

250
150

G4
-c

G4
-M
BP

G4
-s
tr p

G4
-c
hi t

Strep-tactin

E1
beads

15
10

marker
I
FT

I
FT
E1
beads
I
FT
E1
beads
in

E1
beads

G4
-M
BP

marker
I
FT

15
10

chitin

250
150

100
75

100
75

50
37

50
37

25
20

25
20

15
10

50

50

37

37

25
20

25
20

15

15

10

10

G4
-M
BP

h it
in
G4
-c

FT
beads

marker
I
G4
FT
E1
G4
-st
I
rp
FT
E1
G4
I
- ch
i ti
FT
n
E1
G4
I
-M
FT
BP
E1

100
75

E1

100
75

E1
I
FT
E1
I
FT

250
150

marker
I
FT
E1
G4
-s
I
trp
FT

G4

G4
-s

Ni Beads

250
150

G4

I

marker
I
tr p
FT
E1
beads
G4
I
-M
BP
FT
E1
beads
marker
G4
-c
I
hit
in
FT
beads

FT
beads

I

G4

G4
-c
h it
in

G4
-M
BP

G4
-s
trp

marker
I
FT
E1
beads
I
FT
E1
beads
marker
I
FT
beads

15
10

Figure 3-21. SDS-PAGE gel and SV5 western to prove the specificity of the affinity tags
and the possibilities to use them as purification tags
I: initial sample; FT: flow through; E: elution; beads: boiled beads

* Initial samples of G4 and G4-MBP were swapped when loading in the gel
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The affinity purifications using the I.P. tags indicated that the tags bound
specifically to the specific resin while most of the non-specific material was washed off.
Although the hexa-Histidine tag purified more of the scFv, there were also more
contaminants present. All the I.P. tags had comparable yields but strep-Tactin gave a very
clean product with washes at physiological conditions. A strong band of approximately
14kD was present in the fraction where the beads were boiled. This band corresponds to
material released after boiling the strep Tactin beads, having not relation to the sample
previously eluted. Chitin proved to be a high affinity matrix but with a very harsh elution
protocol, due to the need of boiling to release the material.
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3.7 Discussion
This chapter was concerned with:
•

Creation of expression vectors, pRosa, that allowed the simple cloning of
single chains selected from pDAN5 libraries.

•

Study of the influence of Immunoprecipitation tags, strep tag II, CBP, GST,
MBP and CBD, in the binding to the antigen when expressed fused to the
single chains

•

Use of the tags as purification handles.

•

This chapter describes the creation of the multi-functional protein expression
vector pRosa.

The vector was engineered to allow directional sub-cloning of DNA encoding
single chain antibody proteins derived from pDAN5. In addition, the vector was designed
to allow substitution of different purification or I.P. tags. The pRosa vector, derived from
pET28, harbors the strong T7 promoter that enables the over-expression of the gene in T7
polymerase background (e.g. BL21 (DE3)) as well as two tags, hexa-Histidine and SV5.
The vector was also designed with the possibility of C or N terminus cloning of the I.P.
tags by substitution of the gene3 or the flag tag. The tags for the experiments were cloned
at the N terminus. N termini tags can facilitate the correct folding of the protein fused to
them.
The pDAN5 vector is used for display and is the origin of the scFvs antibodies.
The pDAN5 vector contains a hexa-Histidine and an SV5 tag at the C terminus of the
scFv. The PDAN5 vector was modified for these studies by the introduction of NcoI,
AgeI and SfiI R.S. and the gene encoding the flag tag at the N terminus of the scFv. The
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introduction of the flag tag was designed to allow easy substitution for any of the I.P. tags
under study. The resulting vector was named pDAN6. PRosa6 was created by the
introduction of the flag tag-scFv-His tag-SV5 tag encoding DNA fragment form pDAN6
into pET28.
The MBP, GST, CBD, Strep tag II and CBP tags were chosen for these studies.
These have a wide range of molecular weight, going from very large (MBP, 43kD) to
very small (strep tag II, 2.4kD). While small tags should not interfere with the binding of
the antigen to the antibody large ones may, however large ones might be of help in
solubilizing and stabilizing the protein fused to them10. These tags also have high affinity
for their correspondent matrices as well as diverse types of elutions, from mild to harsh,
which might determine in which step to use them in a double tag purification process.
In some cases the affinity tag has been found to partially cover a biologically relevant
binding site of the target protein, thus “masking” a functional ligand binding or cofactor
binding site11. For that reason each tag while fused to the single chains needs to be
checked not only for the right size of final protein and functionality of the tag, but also
for no interference on the binding of the antibody to the antigen.
The size of the expressed protein-tag fusions were analyzed by Western Blot
analysis using α-SV5 antibody as secondary antibody. The clones containing the Strep
tag II, CBP, and MBP tags produced expressed protein of the expected size. The GST
fusion failed to express. Results show that I.P. fusion proteins that expressed, also bound
their corresponding antigen when analyzed by ELISA, single chain antibody-I.P. tag
fusions, produced higher ELISA signals compared to scFv proteins with no tag,
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concluding that the presence of most of the chosen tags was not detrimental to the
binding to the antigen.
It is possible that the I.P. tag fusion aids protein solubility and/or folding. The
signal obtained from the interaction with the antigen in the ELISA assay was better for
the construct with the MBP tag followed by CBD, Strep tag II, construct with no tag and
CBP. CBP and GST tags were discarded as the expression yield was not sufficient for
these studies.
Further studies were carried out to determine if the tags had similar effect while
fused to different single chains. The strategy for switching out the single chains included
directional cloning by double digestion with BssHII and NheI enzymes. However, a
second BssHII site present in the LacI gene of pRosa6 needed to be removed. The
removal of the LacI gene BssHII site created pRosa7. The tags were added into this
mutated vector by digestion from the pRosa6 vectors.
The three different single chains, D1.3, 4M5.3 and G4, were cloned into pRosa7 and
expressed fusions with each I.P. tag. Expression of the panel of scFv-tag fusion proteins
was analyzed by Western Blot assay and ELISA. Results indicated that the tag fusions
didn’t hinder production of any of the single chain proteins and in some cases lead to an
increase, (indicated by a stronger signal in the Western Blot). None of the tag-fusions
impeded scFv activity when analyzed by ELISA.
PRosa8 was created by deletion of gene3. Gene 3 is only needed for the display of
the single chain on the surface of M13 bacteriophage and it was included in the vector to
give it more versatility with the possibility of substitution with C terminus I.P. tags, but is
was not necessary for the present studies. Gene 3 was deleted by simple digestion with
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NotI restriction enzyme. Expression of the scFv-tag panel in pRosa8 gave similar results
to pRosa7 proving that gene 3 was not required.
It has been demonstrated that the functionality of the scFvs is not impeded by the
I.P. tag fusions. In contrast, it was necessary to show that the I.P. tags were also
functional when expressed as scFv fusions.
The aim of this analysis was not only to prove functionality of the tags but even
more to determined which I.P. tag would perform best on the capture and purification of
I.P. complexes. The requirements needed on the tag function included to enable protein
purification in a simple process including mild wash and elution steps.
It was preferable to use a tag that required mild wash and elution conditions and
therefore with a greater chance of recovering intact protein complexes. The idea was to
try a double purification process where the first purification step could release intact
complexes and achieve a cleaner product with a second purification step.
The scFv protein purification using the I.P. tags fused to them was compared to a
standard purification method using the hexa-Histidine tag (located at the C terminus of
the scFv) (Refer to Figure 3-19). The scFv-tag fusions were extracted from the periplasm,
captured by the specific beads of each tag, washed and eluted, using gravity flow. The
proteins captured by the strep-tactin and amylose beads were eluted using specific
buffers. In contrast, proteins captured by the chitin matrix were released by boiling (due
to the lack of cleavage site in the CBD). All of the bead matrices captured and purified
the specific tagged fusion proteins. There was no cross-reactivity between I.P. tags and
non-specific matrices.
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In conclusion, the purification showed that MBP and strep tagII required mild
washed and elutions in order to purify tagged scFv. Strep tag II required the mildest
conditions. Chitin matrix was very effective for purifying CBD protein fusions. However,
the use of CBD tags is limited to either the second stage of a double purification or a
single purification, due to the harsh elution conditions that cause complete denaturation
of the complex.
All the cloned tags, MBP, strep tagII, and CBD were proven to be functional
when expressed as scFv fusions.
Strep tag II stands out as the tag with closer characteristics to the ideal tag for the
purification of protein complexes (Refer to Chapter 1, Table 1-2). It is a very small tag,
therefore no interference with the binding of the antigen to the antibody is expected.
Purification is simple and provides clean product in a single step. It is done under
physiological conditions, being able to keep the protein complex intact, therefore
allowing for a second purification step. Based in all these reasons strep tagII was the tag
of choice for purification of I.P. complexes in this thesis.
SV5 tag, although not tested in these previous experiments, will be the second tag
chosen for protein complex purification in a double purification format (Refer to Chapter
5). SV5 is a very small tag (14 aminoacids) that interacts with high affinity with anti-SV5
antibody1. It is cloned downstream of the scFv in the pDAN5 and pRosa vectors, opposite
to the I.P. tags. Purification using two tags, each at opposite site of the scFv, will assure
the purification of complexes that interact only with full length scFvs. Its presence
doesn’t interfere with the antibody function and it is usually used as detection tag in
Western blots and ELISA. Elution is done in harsh conditions with high salt and low pH
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buffers which disrupt the complex, for this reason it will be used as a second step in a
double purification process.

3.8 Abbreviations:
R.E: restriction enzyme
CBP: calmodulin binding protein
CBD: chitin binding domain
MBP: maltose binding protein
scFv: Single chain variable fragment
kbp: kilo base pairs
TB: tuberculosis
ELISA: Enzyme-Linked ImmunoSorbant Assay
HRP:Horseradishperoxidase.
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Chapter 4.

Selection and Analysis of scFvs

4.1 Introduction:
Several selections of scFvs antibodies against different targets were carried out to obtain
multiple single chains for these studies. Two different types of selection were used.
-

Immunotube selection, in which the target antigen is bound to a plastic
surface

-

In solution selection, in which the biotinylated target antigen is captured
by streptavidin-coated magnetic beads.

Immunotube selection against tuberculosis TB antigen RV2607 produced a scFv, G4.
This scFv was used to study the influence of the tags (Refer to chapter 3, section 3.6.1).
Other selections were performed “in solution” against five additional Shewanella proteins
(SO0256, SO0316, SO2603, SO0090, SO1268). Multiple single chains were obtained by
this manner and the specificity of the antibody for its corresponding antigen was checked
using flow cytometry and ELISA assays. Singles chain antibodies selected against two of
the five Shewanella antigens were cloned into pRosa8-strep vector for further
immunoprecipitation experiments. All the selections were done using a large phage
antibody library1.
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4.2 Immunotube selection against RV2607:
ScFv antibodies were selected against TB RV2607 antigen in immunotubes as
described in chapter 2: immunotube selections. During immunotube selection, the antigen
is coated over the immunotube surface and the library is incubated inside the tube. Wash
and elution processes are carried out within the immunotube to recover the scFvs that
bind specifically to the target antigen (Refer to Figure 4-1).

a)
b)
washes

incubation with library

c)
g)

new antigen coated tube

d)
trypsin

f)
elution

e)

Figure 4-1. Schematic of immunotube selection: a)Incubation of phage-scFv library with antigen
coated immunotube, b) Removal of unbound phages, c) Wash in immunotube to remove non-specific
binders, d) Removal of wash buffer.

95

Following three rounds of selection, 94 clones were isolated for further screening to test
the binding activity of the recovered scFvs against the target antigen and alcohol
dehydrogenase (negative control), by scFv ELISA. Binding events were reported using
horseradish peroxidase (HRP) conjugated to anti-mouse immunoglobulin. Positive clones
were identified as those producing an HRP signal at least 3 fold higher than the negative
control (data not shown). PCR amplification with pDpH5’ and pDpH3’ primers (flanking
antibody gene) determined which of the selected clones contained full length scFvs
(containing both, VH and VL genes). The clones, A7, G4, G12, gave PCR product of the
expected size (approximately 800 bp) whereas clone B2 gave a PCR product of smaller
size indicating VL or VH deletions. (Refer to Figure 4-2). The full length clones, A7, G4
and G12 were fingerprinted with BstNI restriction enzyme. Results show that A7 and G4
are the same scFv clone while G12 has a different pattern, corresponding to a different
single chain (Refer toFigure 4-3)

1 kbp

B2

F1 G1

A7

H1

G4

A2

B2

G12

+

E2

Figure 4-2. pDpH5’/pDpH3’ amplification of ELISA positives
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A7

G4

G12
A7
Pattern 1

G4
G12

Pattern 2

Figure 4-3. BsTN1 R.E. digestion of the full length single chains. 2 different fingerprints were
identified.

G4

G12

s. p.e..

41.7
32.1

p.e. s.

scFv-SV5-His
VH-SV5-His

41.7
32.1
18.3

Figure 4-4. : SV5 westerns on clones G4 and G12 (marker: kaleidoscope Prestained Standard (BIORAD))

Each of the two different scFv clones, G4, and G12, were grown in 50 ml of 2xTy media
and induced with IPTG (Chapter 2: protein expression). The expressed protein was
recovered from the cell periplasm and both, the media supernatant (s) and the periplasmic
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extract (p.e.); (Chapter 2: periplasmic extraction) were analyzed for the presence of scFv
protein by SV5 Western blot (chapter 2: Western blot) (Refer to Figure4-4).
Both scFvs, G4 and G12 produced protein of the expected size, 35 kD, within the
periplasmic extract. The G4 scFv was chosen as a candidate, because it exhibited higher
expression levels and consistently good antigen recognition, to demonstrate that the scFvs
remained functional when expressed as tag fusions (Refer to chapter 3, section 3.5).

4.3 Selection against Shewanella antigens “in solution”
In contrast to the immunotube selection previously described (chapter 4, section
4.2), scFv antibodies were selected against target antigens “in solution”. ScFv antibodies
were selected against five Shewanella antigens in this manner. Antigens were 1)
biotinylated, 2) allowed to interact with library phages, 3) incubated with neutravidin
coated magnetic beads (Dynabeads, Dynal). (Refer to chapter 2: Selection of antibodies
using neutravidin magnetic beads). The bead-antigen-scFv complex is formed in solution
and moved to different wells of the selection plate by the use of magnets. (Refer to
section 4.6) where it is washed and eluted from the beads.
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Biotinylated antigen
M13 bacteriophage

A

A

Dynal magnetic bead
Phage-displayed single chain antibody
A

Covalently linked neutravidin

Figure 4-5. Schematic of interaction of antibodies with biotinylated antigens bound to neutravidin
beads

4.4 Biotinylation:
Each target antigen was biotinylated using the EZ-link Sulfo-NHS-LC-LC-biotin
kit (Pierce). The protocol was designed for protein concentrations of at least 2mg/ml and
suggested an increase of the biotin linker, in the case of more diluted samples, but with
no guidance on amounts. The five target antigens were provided at concentrations more
diluted than those recommended (as shown in to Table 4-1).
#
1
2
3
4
5

protein
SO0256
SO0316
SO2603
SO0090
SO1268

M.W. (D)
38915
19710
19379
20527
53195

conc.
mg/ml
1.94
0.28
0.77
0.47
2.27

Table 4-1. Shewanella proteins information (concentrations before dialysis)

The conditions for biotinylation were determined as follows. The protocol
suggested using at least a 20x excess of biotin linker for concentrations of 2 mg/ml,
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however it was decided to increase the amount linearly. The lowest (0.28 mg/ml) and the
highest (2.27 mg/ml) protein concentrations (before dialysis) were assigned an excess of
60x and 30x of biotin linker respectively (Refer to Table 4-2). An equation was defined
and amount of linker excess, determined for each case. Biotinylation was carried out
according to the manufacturer’s instructions.
#
1
2
3
4
5

protein
SO0256
SO0316
SO2603
SO0090
SO1268

times
linker excess
35
58
51
55
30

Table 4-2. Excess of biotin linker used for each protein

The presence of biotinylated antigen was analyzed via Western blot with
streptavidin conjugated to alkaline phosphatase reporter (as shown in Figure 4-6). Results
show that each protein was biotinylated and gave signal of expected molecular size.

250
150
100
75

#
1
2
3
4
5

50
37

protein
SO0256
SO0316
SO2603
SO0090
SO1268

M.W. (D)
38915
19710
19379
20527
53195

25
20
15
10

1 2 3 4 5

Figure 4-6. Western blot analysis of the biotinylated antigens. Loaded approximately 200ng of each
protein.

100

The concentration of each biotinylated protein was quantified using two methods.
The total protein within each sample was analyzed using BCA Protein assay kit(Pierce).
In contrast, the concentration of the purified protein was analyzed by SDS-PAGE to
1) Check for purity and the presence of proteolysis
2) Determine the concentration by colorimetry (comparing the protein band intensity
against known BSA standards). Two SDS PAGE gels were used to analyze antigens with
numbers 1, 3, 4, 5 against BSA standards (samples 2-5). Protein 2 was not analyzed using
this method.
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BS

#

BS

#

#

a b c d e f g h i

a b c d e f g h i

gel 1
a- marker f- prot #1, ~1ug
g- prot #1, ~0.1 ug
b- 2.5 ug
h- prot #3, ~1ug
c- 1.25ug
d- 0.312 ug i- prot #3, ~0.1 ug
e- 0.078 ug

#

gel 2
a- marker f- prot #4, ~1ug
b- 2.5 ug
g- prot #4, ~0.1 ug
c- 1.25ug
h- prot #5, ~1ug
d- 0.312 ug i- prot #5, ~0.1 ug
e- 0.078 ug

Figure 4-7. SDS- PAGE analysis for protein quantification by colorimetry

The amounts of protein loaded were based on those values produced using the BCA assay
kit.
prot#
1
2
3
4
5

ug/ml
1020
230
230
224
720

ug/ul
1.02
0.23
0.23
0.224
0.72

Table 4-3. Antigen concentrations calculated by BCA assay.

SDS-PAGE results demonstrate that the proteins remain intact and that the concentration
of each protein corresponds to that calculated using the BCA kit. The concentration of the
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antigens must be known in order to calculate the level of Biotinylation. In addition, it
allows for control of the amount of antigen used in each selection.
The level of protein Biotinylation was calculated for each antigen using the EZ Biotin
Quantification Kit (Pierce) (Refer toTable 4-4).
protein #
1
2
3
4
5

biotin/ prot. molec.
2.3
6.3
21.5
20.6
0.7

Table 4-4. Number of biotins per protein molecule for each of the antigens

The ideal biotinylation level was 1 biotin per protein molecule. However the levels
ranged from 0.7 to 21. The study was continued despite having “non-ideal” biotinylation
levels in some cases, because of the limited amount of antigen available.
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4.5 High throughput selection of scFvs
Selections against the five antigens were carried out simultaneously using
KingFisher® (Thermo–Labsystems). Plastic covered magnetic rods allow the transfer of
magnetic beads from well to well (Refer to Figure 4-8).

Binding

Moving

Washing

Incubating

Figure 4-8. Schematic of the KingFisher® working principle. (From http://www.thermo.com)

Selection is performed in KingFisher® plates. (Refer to Figure 4-9). During the
first step, library phages are incubated with biotinylated antigen, and then the complex is
captured upon the neutravidin coated magnetic beads. The phages interacting with the
antigen are transferred from well to well, during several washing steps; only phage
displaying scFv that specifically binds to the target antigen is recovered following acid
mediated elution. The eluted phage is quickly neutralized by addition of Tris solution and
recovered by infection into host bacterial cells, DH5αF. The infected cells containing the
scFv binding population are grown overnight on agar plates with selective media. The
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number of bacterial colonies produced, gives and indication of the numbers of scFv
binders recovered from the selection.

Magnetic Rod
Plastic Tip

Direction
prot# 1
prot# 2
antigen
antigen
+φ
+φ
A
B
strep. beads
strep. beads
C
PBS-T
PBS-T
D
PBS-T
PBS-T
E
PBS-LT
PBS-LT
F
PBS-LT
PBS-LT
G
PBS-LT
PBS-LT
H
0.1M HCl
0.1M HCl
* strep. beads: streptavidin coated beads.

prot# 3
antigen
+φ
strep. beads
PBS-T
PBS-T
PBS-LT
PBS-LT
PBS-LT
0.1M HCl

prot# 4
antigen
+φ
strep. beads
PBS-T
PBS-T
PBS-LT
PBS-LT
PBS-LT
0.1M HCl

prot# 5
antigen
+φ
strep. beads
PBS-T
PBS-T
PBS-LT
PBS-LT
PBS-LT
0.1M HCl

vol
171µl lib + 19µl antigen
incubate 1hr RT
200 µl
190 µl
190 µl
190 µl
190 µl
190 µl
150 µl

Figure 4-9 Schematic of the KingFisher® instrument and plate set up for the selection of scFvs

Three rounds of selection were carried out and the output from each round was
input for the following to allow enrichment of the binding population. In order to increase
stringency of the selection conditions, the antigen concentration was decreased and the
length of the washing steps increased in each subsequent round (Refer to Table 4-5)
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antigen concentration
washes

1st round
600 nM
1 min

2nd round
60 nM
5 min

3rd round
60 nM
15 min

Table 4-5. Variation in concentration and washes between the three rounds of selection

In the third round, a negative control was included to determine the level of scFv
background binding (e.g. scFv that binds to streptavidin on the beads). The output from
the second round was left to interact with beads in the absence of target antigen (negative
control). In order to determine that scFv-phage with selective binding properties have
been recovered; the ratio of scFv-phage that binds antigen is compared to the negative
control. (Refer to Table 4-6).

Protein #
1
2
3
4
5

3rd Round Results
# colonies
antigen/negative
25 x
2x
50 x
3x
100 x

Table 4-6. Ratio between numbers of colonies obtained from third round output over antigen coated
beads versus the one over empty beads (negative)

Results indicate recovery of those scFv-phages that specifically bind to the target antigen
in all five cases. After the third round of selection, the bacteria infected with the output
phages was recovered and stocked.
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4.6 High-throughput screening of scFv
Single chains produced in the third round selection output were tested for binding
activity against the target antigen. The use of multiplex flow cytometry2, allows the
screening of the binding activities of an individual scFv-phage against multiple targets in
one analytical sample. These multiple targets include 1) The target antigen, against which
the scFv was selected, 2) An antibody that recognizes the SV5 tag (that all the scFv are
fused to and 3) Other antigens which the scFv is not expected to cross react. This allows
comprehensive analysis of each individual scFv regarding expression levels, binding
specificity and cross-reactivity of each clone in a simple measurement.
The multiplex screening assay utilizes Luminex carboxylated beads. The beads
are intrinsically color-coded where each has a slightly different amount of either two
dyes. Up to 100 different colored beads are available for multiplexing.
Different bead sets are distinguishable when excited with a red laser. ScFv
antibodies are fluorescently labeled and the fluorescence obtained after excitation with
green laser provided binding information of the single chains to the different bead
sets.(Refer to Figure 4-10).

Figure 4-10:: Excitation of a Luminex bead with green and red lasers (Luminexcorp.com).
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Each scFv antigen produced from the selections, was screened against the four
Shewanella antigens in multiplex, using the flow cytometry method described2. Each
bead set was checked for uniformity in neutravidin coating, using MAG protein
(monomeric azami green) as a standard (data not shown).
Each individual set of neutravidin coated beads was incubated with a different
biotinylated antigen (antigens #2, 3, 4, 5) and the four different bead sets were coupled as
shown in Table 4-7 and Figure 4-18A.
Bead Set
Neutravidin xMAP 129
Neutravidin xMAP 142
Neutravidin xMAP 135
Neutravidin xMAP 180

B-antigen
b-α-SV5
b-antigen
b-ubiquitin
PBS

Table 4-7: Antigens and microspheres used in flow analysis. (b- Stands for biotinylated)

xMAP 142 bead set was coupled to the corresponding antigen #2, 3, 4 or 5 according to
the scFv output being screened. xMAP 129 was coupled to α-SV5 antibody to indicate
the levels of scFv protein expression. xMAP 135 was coupled to ubiquitin as a negative
control and xMAP 180 was included to check that the scFv clones did not cross react
with neutravidin.

4.6.1 Labeling of the single chains (K coil-Alexa 488):
The single chain antibodies need to be labeled with a fluorescent dye in order to be
analyzed by flow cytometry. This was achieved by the use of coiled coils, a bundle of αhelices that are wound into a superhelix3 4 5 (Refer to Figure 4-11).
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Figure 4-11: Coiled coils

Single chains are fluorescently labeled using synthetic E/K coil heterodimeric peptides
that bind with an affinity of approximately 60 pM. Single chains are expressed as E coil
fusions and are mixed with K coil conjugated with Alexa 488. The one to one E/K coil
interaction ensures uniform labeling of each scFv protein.

Figure 4-12: Coil mediated labeling of single chain.
E coil sequence: NH2-EVSALEKEVSALEKEVSALEKEVSALEKEVSALEK-OH
K coil sequence: NH2-KVSALKEKVSALKEKVSALKEKVSALKEKVSALKE-Cys-OH
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K coil was in-house synthesized in collaboration with Dr. J. Schmidt (LANL) using
solid-phase chemistry and labeled at a Cys residue using sulfhydryl-reactive Alexa Fluor
488 maleimide reagent (Molecular Probes) (Chapter 2: K coil-Alexa 488 synthesis).
Analysis of the synthesized peptide before and after labeling was done by mass
spectrometry.
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Figure 4-13: Mass spectrometric spectra of the synthesized K coil, before and after labeling
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An experiment was designed to demonstrate that the E coil and K coil peptides
heterodimerize when the E coil is expressed as a scFv fusion and when the K coil is
conjugated to Alexa 488. A standard scFv, HyHel10, was expressed alone and as either E
coil or K coil fusions. The purified protein of each type, HyHel, HyHel-E coil and
HyHel-K coil, was resolved by SDS PAGE gel for Western blot analysis. The proteins
were transferred to nitrocellulose membrane and incubated with anti-SV5 and K coil488
simultaneously (Refer to Figure 4-14). Results show that the fluorescently labeled K coil
specifically interacts with E coil protein fusions.

incubated with SV5

HyHel

HyHel-E coil HyHel-K coil

incubated with K coil-Alexa 488

HyHel

HyHel-E coil HyHel-K coil

Figure 4-14: Western Blot Analysis of purified single chain-E/K coil fusions.
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4.6.1.1pEP-scFv-E vector
The DNA encoding the scFv antibodies produced in each third round selection
was cloned into pEP-scFv-E coil vector. PEP-scFv-E 6 coil vector is derived from pET28
and allows expression of scFvs as E coil fusion proteins. Expressed scFv-E coil fusions
were then directly labeled with K coil Alexa 488 prior to flow cytometry analysis.
lacI

T7 Promoter
pelB
Bss HII (699)

VL

VH

pEP-scFv-Ecoil
6275 bp

linker
NheI (1427)

Ecoil
SV5
His tag

Kanamycin

Figure 4-15: pEP-scFv-E vector diagram

4.6.1.2Cloning of the scFvs into the pEP-scFv-E vector:
DNA encoding the scFvs was recovered from the infected bacterial cells
following the third round selection against each of the five target Shewanella antigens.
The DNA was digested with BssHII and NheI restriction enzymes and cloned
directionally in the BssHII/NheI restricted pEP-scFv-E coil vector. (Refer to Figure 4-16)
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872
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2322
2027
1353

scFv genes

1078
872

scFv genes

603

Figure 4-16: BssHII/NheI digestion of scFv DNA from selections against proteins 1, 2,3,4,5.

The fragment size of approximately 800 bp, represents full length scFv containing both
domains, VL and VH. To get an idea of the single chain diversity in each selection, DNA
of 12 randomly picked clones were PCR amplified with pDpH5’ and Ecoil3’ primers.
PCR product was digested with BstNI restriction enzyme to produce the DNA fingerprint
of each clone. (Refer to Figure 4-17).
The fingerprint of a number of representative clones was determined prior to screening to
ensure that the population of scFvs representing the binding population was diverse and
did not consist of the same clone (scFvs against antigen #1 were not fingerprinted at this
point).
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Figure 4-17: Fingerprint of single chains coming from selections against Shewanella antigen targets,
2, 3, 4, 5
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The digestion of randomly picked colonies indicated the presence of a large diversity of
single chains in all but in the case of protein # 2. Because of the large diversity within the
potential binding population, 46 individual scFv clones were expressed and analyzed
using multiplex flow cytometry assay (single chains coming from selection against
antigen #1 are not analyzed by this manner)

4.6.2 Flow cytometry and ELISA analysis:
Each scFv-E coil clone as expressed in 1ml of autoinduction media in a 96 deep
well plate. Following over night incubation at 25ºC and 900rpm, the cells were
centrifuged to separate them from the media supernatant containing the scFv-E coil
fusion proteins. The supernatant containing expressed single chain-E coil fusion was
incubated with Kcoil-Alexa488

7

to allow the scFv-E coil proteins to become

fluorescently labeled (Refer to section 4.6.1). The four bead sets (xMap 129, 142, 135
and 180) were combined into one analytical sample as shown in Figure 4-18B. Each
scFv-E coil-K coil-Alexa 488 clone was added to the bead mix and binding events were
allowed to take place (Refer toFigure 4-18.C). Each of the samples was analyzed with
LSR II flow cytometer (BD Biosciences) (chapter 2: LSRII).
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Components
neutravidin

b-shewanella antigen

b-ubiquitin

b−α-SV5

scFv

Conjugated beads and labeled scFv

488

142

129

135

180

Multiplex Experiment

A)

B)

C)
Analysis
LSRII
Figure 4-18: Schematic of a multiplex experiment
A) Conjugation of four sets of beads with target antigen, a-SV5, ubiquitin and neutravidin only.
B) Mixing of the four sets of beads
C) Incubation of the beads with the labeled scFvs
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The dye in the beads was excited with a 633nm laser separating the bead multiplex in
gates after detection with APC-Cy7 and APC filters (Refer to Figure 4-10). A 488 nm
laser excited the fluorescent dye in the beads coming from the single chains and the mean
fluorescence of 5000 beads was detected using a FITC filter. Levels of fluorescence
measured at the different gates gave us information regarding the different binding
events.

population

FITC-A
Mean

Shew. antigen 12,296
α-SV5

28,717

Ubiquitin

2,109

Empty

2,568

Figure 4-19: Data output coming from LSRII representing a positive binding event for a single chain
selected against a Shewanella antigen.
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Fluorescence values coming from the α-SV5 conjugated beads, gave an indication
of the protein expression level due to the presence of SV5 tag fusion downstream of the
scFv-E coil (Refer to Figure 3-19). The background was accounted for by averaging the
signal coming from the b-ubiquitin (xMAP 135) and the neutravidin only (xMAP 180)
beads. The fluorescent value originating from the xMAP 142 bead set (conjugated to the
Shewanella antigen) was normalized by dividing by the corresponding SV5 value.
Positive binders were identified as those clones with a fluorescent signal three or more
times above the background. (Refer to Table 4-8)
Shewanella population
antigen
tested
negative
#2
46
46
#3
46
46
#4
46
36
#5
46
40

positive
0
0
11
8

Table 4-8: Analysis of binders by LSR II flow cytometec. Positive corresponds to the number of scFvs
with S/N three or larger.

No positive binders were identified against Shewanella proteins numbers 2 and 3.
On the contrary, multiple binders were determined for proteins 4 and 5. To confirm the
results, the same single chain clones and 46 extra more coming from the selection outputs
were tested using ELISA assay. ELISA plates were coated with neutravidin prior to the
addition of the biotinylated antigen (chapter 2: SV5 ELISA). ELISA analysis of the scFv
binders against antigens #2 and #3 gave identical results to flow cytometry analysis; no
positive binders were identified Comparison of the flow cytometry and ELISA results
produced similar trends in binding activity against the target antigen for antigens #4 and
#5.
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Those single chain clones that gave a signal of three or more times above
background, when analyzed by ELISA, were fingerprinted to check for diversity. DNA
originating from these clones was PCR amplified with pDpH5’ and Ecoil3’ primers and
the product digested with BstN1 restriction enzyme (Refer to Figure 4-20). (Raw data
coming from ELISA and flow cytometry analysis is reported in Appendix to chapter 4).
The fingerprint of the ELISA positives shows great diversity of single chains against both
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Figure 4-20: Fingerprint of single chains against antigen #4 that were positive in ELISA shown
besides the corresponding ELISA and flow signals. Background is represented by an average of the
signals coming from ubiquitin and neutravidin only beads. 96 clones were tested by ELISA, 46 of
them also by flow.
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Figure 4-21: Fingerprint of single chains against antigen #5 that were positive in ELISA shown
besides the corresponding ELISA and flow signals. Background is represented by an average of the
signals coming from ubiquitin and neutravidin only beads. 96 clones were tested by ELISA, 46 of
them also by flow.
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96 single chains coming from the selection output against antigen #1 were
analyzed by ELISA (Refer to Appendix, Figure 3) only. A summary of ELISA results for
each of the five antigens are shown in Table 4-9. Multiple single chains gave ELISA
signals at least three times above that of the negative control (ubiquitin). Those clones
that gave positive ELISA signal were fingerprinted to check diversity (Refer to Figure
4-22 ). Diversity of the single chains is large, with very few of them having the same
fingerprint.
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Figure 4-22: Fingerprint of positive single chains against antigen #1 represented beside the ELISA
signals. Each signal corresponds to the average of two replicates. (Neutravidin coated ELISA plate
and biotinylated antigen).
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#1
#2
#3
#4
#5

population
96
96
96
96
96

positives
22
0
0
35
56

% positives
22.9
0.0
0.0
36.5
58.3

Table 4-9: Summary of results from ELISA assays on Shewanella proteins

The single chains giving positive interaction with antigen #5 were also checked
by ELISA against Shewanella cell extract in place of the protein antigen. Bacterial
sample of S. oneidensis MR-1 was provided by Dr Frederickson (Pacific Northwest
National Laboratory). Bacteria was grown and stored as indicated (chapter 2: Preparation
of Shewanella oneidensis MR-1 cell pellet). Escherichia Coli (E. coli, DH5αF) was also
grown and stored and used as a negative control. Bacterial pellets were thawed an
sonicated. Concentration of the total cell protein released to the supernatant was
estimated by BCA assay (Pierce). ELISA plates were coated with S. oneidensis and E.coli
(Chapter 2: SV5 ELISA) (Refer to Figure 4-23). ELISA steps were followed as
previously described.

SV5 ELISA over bacterial extract on positives against antigen #5
1.2

Abs. at 405 nm

1
0.8
Shewanella extr.
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scFvs

Figure 4-23: ELISA against Shewanella cell extract using scFvs that were positive against antigen #5.
Each signal is the average of two replicates.
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The single chains that gave positive signal when assayed against biotinylated
antigen in ELISA did not show specific interaction in the assay with the Shewanella cell
extract. Some of the single chains showed, in any case, some specificity for the
Shewanella cell extract versus the E. coli one.
The availability of multiple single chains specific for at least three of the
Shewanella antigens made the study much more complex. In order to develop the method
and with no specific information about the levels of expression of the antigens in the real
Shewanella bacteria, the study was continued with two of the Shewanella antigens and
the respective single chains. Antigens #1 and 5 were chosen to continue developing the
immunoprecipitation method described in chapter 3.
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4.6.3 Cloning of the scFvs into the tag vector (pRosa8-scFv-strep)
Several single chains that were positive against Shewanella antigens #1 and #5
were cloned into pRosa8-strep vector in preparation for immunoprecipitation. The single
chain candidates were chosen on the basis of being different (identified by fingerprinting)
and having specific antigen binding by ELISA. The DNA encoding the single chains was
digested with BssHII and NheI restriction enzymes, out of the corresponding pEP-E
vector, and directionally ligated to NheI/BssHII digested pRosa8-strep vector (Refer
toFigure 4-24).

against antigen #5

against antigen #1
vector

B8 C8 B10 F3 F11 G5

A3

B8

D1

D3

D5

G5

G9

pRosa8-strep

scFvs

Figure 4-24: BssHII/NheI digested fragments of pRosa8-strep vector and of single chains against
antigens #5 and #1.

Following ligation and transformation, the DNA was prepared and sequenced
using T7 promoter and T7 terminator primers. Sequence data was analyzed using
ContigExpress and the alignment of sequences using AlignX (Vector NTI, Invitrogen)
software (Refer to Figure 4-25 and Figure 4-26). Seven different scFv candidates were
chosen for antigen #1 and six scFvs for antigen #5.
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Figure 4-25: Alignment and phylogenetic tree of amino acid sequences of single chains selected
against antigen # 1
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Figure 4-26: Alignment and phylogenetic tree of amino acid sequences of single chains selected
against antigen # 5

126

Analysis of the single chains indicated the presence of all the genes expected in the
vector with the right sequence. The alignment of single chains indicated the diversity of
them, with multiple variations in the sequences of the heavy and light chains from one
single chain to another.

4.7 Discussion
The work described in this chapter is concerned with the generation of single-chain
(scFv) antibodies that selectively bind to TB and Shewanella antigens. Ultimately, these
scFv antibodies will be used to generate scFv-Tag constructs to study protein/protein
complexes by immunoprecipitation (IP). Two different types of selections were carried
out in order to obtain scFvs for these studies. The first selection experiment used
immunotubes coated with the target antigen. This selection was done against protein
RV2607 (a TB antigen) and produced two different antibodies, G4 and G12, against the
target. Initially, Tuberculosis was the choice organism for IP analysis. More information
about protein complexes is needed to be able to understand how TB works and to
decipher the protein network. However, in order to develop the new IP method, TB
bacteria and proteins were required and the availability of these components was limited.
The two anti RV2607 scFvs were not used in the final IP experiments. However, one of
the single chains (G4) was used as a model to check the influence of affinity tags in
antibody binding (Refer to Chapter 3).
In order to successfully develop scFvs for IP experiments, a different selection
method was used and the Shewanella bacterium was adopted as the target organism for
these studies. Shewanella is an important organism for remediation and environmental
clean-up. However, very little is known about the biological and physiological properties
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of the organism. Developing a new immunoprecipitation method using scFv antibodies
selected against Shewanella proteins could help understand the protein complexes of the
organism. One advantage of working with Shewanella includes the fact that the bacteria
can be cultured and isolated under Biosafety Level 1 conditions (as the organism poses
no risk to human health). In addition, numerous purified proteins were also available
from collaborators at the time that these studies were being performed. All of these
factors made Shewanella the choice organism to further develop the immunoprecipitation
method in place of tuberculosis.
The second selection experiment was carried out using five different Shewanella
antigens (proteins renamed #1, 2, 3, 4 and 5) and selection (panning) in solution. Prior to
screening the selection output, fingerprint analysis revealed that the diversity of the scFv
output was varied in all cases except for antigen #2. (Refer to Figure 4-17); indicating
that the selection was successful in generating different scFv clones. Immunotube
selection against RV2607 antigen produced only two different selective single chains (G4
and G12). In comparison, ‘in solution’ panning produced numerous different scFv
antibodies against three of the five antigens under study. Antigen specific binding scFvs
were produced against Shewanella antigens #1, 4 and 5. Positive clones were identified
by ELISA and fingerprinted to check the diversity of the scFv binding population, which
proved to be as large as 30, 22 and 35 different specific scFv antibodies were generated
against the antigen #1, 4 and 5 respectively.
The results given here clearly indicate the superiority of the “in-solution” selection
(using magnetic beads) compared to the immunotube method in selecting numerous
different scFv binders.
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In-solution panning utilizes the biotin-neutravidin interaction to capture the target
antigen onto the magnetic bead. Biotinylation of the antigen allows the protein to remain
in its natural conformation when captured on the neutravidin bead. Furthermore, this
allows the scFv antibodies to interact with the antigen in its native state. During
immunotube surface capture of the antigen, the protein undergoes conformational
changes that are known to cause protein denaturation8.
The uncertainty of the level of coating of antigen in the immunotube could be the
reason why more positive binding scFvs were selected and identified using “in solution”
panning compared to immunotube selection. Selection “in solution” has proven to yield
numerous and more diverse single chain antibodies. Compared to immunotube selections,
in solution panning, allows the antigen to remain in its natural conformation state and
eliminates background binding of non-specific scFvs.
In addition, the use of the KingFisher® allowed selections to be automated and
carried out in high throughput. Automation ensures consistency, reproducibility and
eliminates the human error factor. When comparing the “immunotube” to the “in
solution” method, the difference is in the number of diverse clones selected ( two for
immunotube and more than twenty for in solution) can also be explained by stringency
during “in solution” panning. Antigen was decreased 10 times between first and second
round, and washes were increased successively from one to five and to fifteen minutes
during the “in solution” protocol. On the contrary, the immunotube selection protocol
included constant antigen that did not increase the stringency of the selection conditions.
The output from the selections carried out against the five Shewanella antigens was
analyzed using two different methods, multiplex flow cytometry (scFvs against antigens
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#2, 3, 4 and 5) and ELISA (scFvs against antigens #1, 2, 3, 4 and 5). The scFvs recovered
from the third round selection output were cloned into pEP-E vector to produce E coil
fusions. The single chains were fluorescently labeled for flow cytometry analysis using K
coil-Alexa 488 that was chemically synthesized and conjugated.
The multiplex flow cytometry method had only been recently developed and apart from
the screen that was conducted to generate data for the publication, this was the first time
that it had been used to analyze the scFv output from a selection. This method was used
to screen the scFv outputs produced against Shewanella antigens #2, 3, 4 and 5 and the
same clones were also analyzed by ELISA in order to double check the reliability of the
flow cytometry analysis.
No scFv binders were identified against antigens #2 and 3 when analyzed by flow
cytometry and this result was confirmed by ELISA. This is unusual for this library, which
has usually yielded multiple binders against many different targets, as seen for the other
antigens. Re-examination of the antigen (Figure 4-6) shows that there was nothing
unusual about these antigens: they were well biotinylated, appeared to be well purified,
and were similar in size to some of the other successful antigens.
Out of the 12 randomly picked scFv clones fingerprinted for antigen #2, 10 were exactly
the same (Refer to Figure 4-17). The poor diversity of the scFvs obtained against antigen
#2 explains why no binders were identified for this antigen. It is possible that the same
scFv clone was recovered due to erroneous properties that have allowed it to become
enriched during the selection process.
The flow cytometry results were compared to positive ELISA results for antigens
4 and 5. Generally, flow cytometry identified the same positive binders for antigen
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number 4; 11 of the 12 scFvs positive in ELISA were positive by flow cytometry. In
contrast, only 8/12 of the 12 ELISA positive binders were identified by flow cytometry
analysis for antigen number 5 (refer toTable 4-8). The paper described by Ayriss et al
demonstrated that the binding profile (the level of antigen binding) of positive scFvs were
identical by ELISA and Flow cytometry. The binding profile of scFvs identified by both
ELISA and flow cytometry, in this study, do correlate but the similarities and differences
are subtle. This observation could be due to differences in expression levels between the
proteins prepared for both the ELISA and flow cytometry experiments. The expressed
protein samples were prepared on different days and the expression conditions were
different; the length of expression was 3 days for Flow Cytometry and 2 days for ELISA.
The length of expression seems to be a critical factor in producing identical yields of
protein for obtaining identical binding profiles. Because proteolysis might have degraded
some of the expressed scFvs with time, the binding results can only be directly compared
between ELISA and flow cytometry when they are corrected for the expression level. The
levels of protein expression were not determined for the scFv samples tested by ELISA
because it would require doubling the amount of scFv samples and antigen consumption.
In contrast, the multiplexing capability of the flow cytometry allowed the expression
levels to be determined at the time of binding analysis. Considering the amount of
information that is generated in one analytical sample, the advantages of using multiplex
flow cytometry as screen method are numerous and include lower consumption of
antigens, time and technical labor. These factors made the screening method very
attractive and worth exploring.
An ELISA, using Shewanella cell extract in place of target antigen #5, was
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carried out using a panel of scFv antibodies selected against antigen #5. No specific
binders were identified and the negative results could not be concluded because it is not
known at what level the amount of ‘target antigen #5’ naturally exists within the
Shewanella cell extract. The success of an ELISA is dependant on both the amount of
target antigen available and the affinity of the scFv for the antigen. If the target antigen
#5 is represented at negligible levels then the ELISA would not be sensitive enough to
detect the presence of the target antigen within the cell extract no matter what the affinity
of the scFv was. Furthermore, even if present at reasonable levels, it is possible that
insufficient amounts of the antigen were bound to the ELISA plate due to the presence of
so many other competing proteins. There was no direct correlation seen between the
number of different scFvs recovered and the level of antigen biotinylation.
This study has been successful in producing multiple single chains that are
specific against three different Shewanella antigens. The study was continued with 7 and
6 different single chains produced from selections against antigens #1 and 5 respectively;
as they came from populations of scFvs that were the most diverse. The single chains
were cloned into pRosa8-strep vector and sequenced. All of the scFv clones were in
frame and contained the pelB, strep-Tag, VL, Lox511 recombination site, VH, SV5 and
His Tag as expected. The amino acid sequences of the scFvs were aligned and showed
the difference in sequence variability between the light and heavy chains, of one scFv
compared to the next. These scFv binders will be used to generate scFv-Tag constructs to
study protein/protein complexes by immunoprecipitation (IP)
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4.8 Appendix to Chapter 4
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Figure 4-27: Raw ELISA and flow cytometry data corresponding to the scFvs selected against
antigen #4. Flow data has been represented in two different graphs in order to be able to use
different scales.
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SV5 ELISA in scFvs from selection against antigen#5 (A-D)
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Figure 4-28: Raw ELISA and flow cytometry data corresponding to the scFvs selected against
antigen #5. Flow data has been represented in two different graphs in order to be able to use
different scales.
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Chapter 5. Immunoprecipitation of protein
complexes
5.1 Introduction
This chapter describes the use of the double tag system, StrepII and SV5 tag fused
to single chain antibodies (scFvs), for the capture of immunoprecipitation (IP)
complexes. A proof of principle strategy was created to demonstrate how the IP tags,
StrepII and SV5, can be used to capture a known antibody/antigen complex comprising
two single chains antibodies D1.3, and HyHel10 and their common antigen, chicken
lysozyme. The aim of the proof of principle experiment was to demonstrate that the D1.3
scFv was able to purify in complex with its antigen (Chicken lysozyme) and co-purify
with the second anti-lysozyme scFv, HyHel10. A scheme of the proof of principle
experiment is shown in Figure 5-1.
The double tag purification system was applied to a real IP experiment using
Shewanella oneidensis MR-1 (S. oneidensis) extract for the capture of protein-protein
complexes. ScFv antibodies specific for S. oneidensis antigens #1 and #5 (Refer to
chapter 4) were selected (using phage display), expressed and purified as SV5 and strep
tag fusions (refer to Chapter 3 section 3.4.1). These selected scFvs were used in parallel
IP experiments in an attempt to generate protein-protein complexes from Shewanella cell
extract. The results and conclusions of the S. oneidensis IP capture experiments are
described here.

135

H
H
H

H
H
H

lysozyme

HyHel10

ap
His tag
His
tag

SV5
tag

D1.3

H
H

H
H

H

proteins from cell extract

H

strep
tagII

H

H

α-SV5 coated
beads

strep tactin
beads
H H HH

H H HH

H

H

H
H
H
H

H

H

H

HH HH

2nd purification

washes

washes
α-SV5 coated
beads

strep tactin
beads

H HH

H

HH

H H HH

H

H
H

H
H
H
H

H

H

HH HH

H

H

Figure 5-1: Schematic of the double tag purification process.
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5.2 Immunoprecipitation of D1.3-lysozyme and Hyhel-10
using strep tag II and SV5 tag
As described in Chapter 3 section 3.4.2, the scFv tag clones were prepared for use
in these IP, proof of principle experiments. The Strep and SV5 Tags were cloned at the
amino (N) and carboxyl (C) termini of the scFv gene, encoding D1.3, respectively. The
gene encoding alkaline phosphatase (AP) was cloned at the C terminus of HyHel10. The
HyHel10-AP clone did not contain either StrepII or SV5 tag.
Both of the scFv fusion proteins, Strep-D1.3-SV5 and the HyHel10-AP, were
expressed and recovered from the cell pellet using the Emulsiflex Homogenizer
(Avestin). The cell extract was filtered and each scFv protein was subsequently purified
using Ni-NTA chromatography (via the hexa-Histidine tag). Generic elution conditions
were used, so the proteins were not very pure. However, for the purposes of the
experiments described here, this was not too important, as the purified protein was mixed
with E. coli extract to mimic more closely a real IP.
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Figure 5-2: Gel quantitation of the purified single chains. Proteins were recovered at a concentration
of 0.3µg/µl (Strep-D1.3-SV5) and 0.1µg/µl (HyHel10-AP).
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The IP complex was created by mixing Escherichia coli (E. coli) cell extract with
each purified scFv (Strep-D1.3-SV5 and HyHel10-AP) and lysozyme. The sample was
incubated with prepared StrepTactin beads (Refer to chapter 2: StrepTactin purification)
rotating for one hour at 4°C. Three samples were prepared in parallel in order to compare
the purification of IP complexes following two separate single and one double tag
purification.
Two different types of single tag purification were performed. The first single tag
purification utilized the Strep tag II using micro columns containing Strep-Tactin and
mild elution conditions (Refer to chapter 3, section 3.5). In contrast a second, single tag,
purification was carried out using SV5 tag, using Protein A tips (Phynexus) coated with
anti-SV5 antibody, and harsh elution conditions (Refer to chapter 2: SV5 purification
using protein A tips).
In the case of double tag purification, the mixture of single chains (D1.3 and
HyHel10), lysozyme, cell extract and beads was incubated with rotation for an hour at
4°C. The protein complex was first purified using the Strep tag II in D1.3 and the eluted
fraction was recovered and carried through a second purification using protein A tips
(Phynexus) coated with α-SV5 antibody. The proteins recovered in the eluted samples
were analyzed by SDS-PAGE (4-12% Bis-Tris) and stained with silver for visualization.
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Figure 5-3: SDS Page analysis of model complex immunoprecipitation, comparison of double and
single tag purifications. Left figure is the expected bands, right hand one is the actual experiment.
1µg of each scFv and equimolar amounts of lysozyme was added to 50 µl of cell extract. Elution from
strep Tactin matrix was in 100µl and in 30 µl from the α-SV5 column. Samples were loaded in equal
volumes (10 µl). Controls of each component were added HyHel10 (1µg), α-SV5(2.5µg), D1.3 (3µg).
Gel was developed by silver staining (chapter 2: silver staining)
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Results from single and double purification are represented in the silver stained
protein gel (Refer to Figure 5-3). The initial E.coli cell extract sample shows the large
density of proteins present. Samples 1, 2 and 3 show the proteins present in the eluted
fractions following single tag purification with strep tag II. The purification is very clean
and the only bands present in the eluted samples correspond to the expected products,
HyHel10-AP, Strep-D1.3-SV5 and chicken lysozyme. Following single tag purification
using SV5 tag (Refer to SV5 purif.) the three components of the model complex,
(HyHel10-AP, Strep-D1.3-SV5 and lysozyme) are visible, in addition to bands
corresponding to the anti-SV5 heavy and light chain (originating from the anti-SV5
antibody on the Protein A tips). Results show that the single tag purification with SV5 tag
is not as clean as the single tag purification using Strep tag II. In contrast, double tag
purification produced very clean and well defined bands corresponding to the 3 IP
components. This type of purification gave a very clean and concentrated product
contained within a small volume (30ul). The proteins shown in lanes 8, 9, 10 and11
correspond to the positive control samples included to allow identification of the three
components (HyHel10-AP, Strep-D1.3-SV5 and chicken lysozyme) used in this
experiment.
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5.3 Immunoprecipitation of S.oneidensis MR-1 protein
complexes
5.3.1 Expression and purification of scFv-Tag fusions:
Four scFvs (G5, A3, B8-1 and D5) selected against S. oneidensis protein #1 and
three (B8-5, F3 and F11) selected against. S. oneidensis protein #5 were fused to both
Strep tag II (N terminus) and SV5 Tag (C-Terminus) by directional cloning into pRosa8strep (Refer to chapter 3, section 3.4.1). The scFv-tag fusions proteins were expressed
within autoinducing or 2xTY-IPTG media (Refer to chapter 2: protein expression). No
differences in expression yields were observed depending upon which type of expression
media was used (data not shown). The scFv proteins were extracted from the periplasm
(Refer to chapter 2: periplasmic extraction) and purified by affinity chromatography,
using the hexaHistidine tag. Two different formats of Ni purification were tested: 1) NiNTA column purification with a large column bed (500 µl) and 2) Ni beads in tips with a
small column bed (5ul, Phynexus tips).
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Figure 5-4: Purified scFvs against antigens # 5 and #1 in Western Blot and gel code stained gel. B8
and A3 samples purified using Ni-NTA tips and all the others with agarose beads in column.
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The purification results material was analyzed by SDS-PAGE and the proteins
were visualized following stain with Gel Code Blue Stain Reagent (PIERCE). Following
SDS PAGE separation, the proteins were transferred to nitrocellulose membrane and the
scFv proteins were identified by Western Blot with anti-SV5 antibody. (Refer to Figure
5-4). Due to the large volume of periplasmic extract, column purification was the method
most regularly chosen.
The S. oneidensis MR-1 bacteria were cultured (Refer to chapter 2: Amplification
of S. oneidensis MR-1) and the whole cell extract was prepared by homogenization
(Emulsiflex homogenizer, Avestin). The total protein concentration of the whole cell
extract was determined using the Bradford assay (BioRad). However, the concentration
of each of the two target antigens #1 and #5 within the whole cell extract was not known.

5.3.2 I.P. Experiment #1:
The aim of the experiment was to determine whether two different sets of scFvs
specific for S. oneidensis antigens #1 (clones A3, B8-1, D5 and G5) and antigen #5
(clones B8-5, F3 and F11) could be used collectively to generate and capture IP
complexes from S. oneidensis cell extract.
The first set of scFvs comprised those four different clones generated against S.
oneidensis protein #1; A3, B8-1, D5 and G5. Whereas the second scFv set consisted of
three different clones specific for S. oneidensis protein #5 (B8-5, F3 and F11). Each of
the two different scFv sets was tested, in parallel, for their ability to form IP complexes
with S. oneidensis cell extract. The mixture of each scFv candidate was incubated with
Shewanella cell extract for two hours at 4°C and then with StrepTactin beads, rotating
overnight at 4°C. The IP complex was purified using the double tag (strep tag II and SV5
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tag) system previously described (Refer to Chapter 3).The flow through and eluted
proteins were resolved by SDS-PAGE and analyzed by Western Blot analysis (data not
shown).
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Figure 5-5: SDS PAGE gel of I.P experiments. First lane marker, second, I.P. experiment using
protein #1 and specific scFvs, third, I.P. experiment using protein #5 and specific scFvs. 1µg of each
scFv was added to 10 ml of S. oneidensis (1mg/ml). Samples were incubated over night with strep
Tactin beads

Results of SDS PAGE analysis show that the only proteins present in the eluted
fraction are the two proteins corresponding to the Heavy (50kDa) and Light (25kDa)
chains of the anti-SV5 antibody used to capture the IP complex. These proteins were also
observed in the proof of principle experiment described previously. No other proteins
were visible. Due to this negative result, all fractions produced at each step of the IP
process were checked for the presence of scFv-Tag protein by SDS PAGE and Western
blot analysis (data not shown). None of the 7 different scFvs, or any other protein
antigens, was detected.
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5.3.3 I.P. Experiment #2:
The technical procedure of IP experiment #1 was modified by reducing 1) the S.
oneidensis cell extract volume from 10ml to 1ml and 2) the incubation time with the
StrepTactin beads from overnight to 1 hour at 4°C. The same two scFv sets were
prepared as used in experiment #1. However samples were also prepared, for each scFv
set, where the S. oneidensis cell extract was spiked with the target S. oneidensis nonbiotinylated antigen #1 (clones A3, B8-1, D5 and G5) or #5 (clones B8-5, F3 and F11). In
addition, each scFv set was mixed with S. oneidensis cell extract spiked with the nontarget, non-biotinylated antigen.
Each scFv was added to S. oneidensis cell extract. The scFv protein set and S.
oneidensis cell extract were mixed and then either PBS, target or non-target antigen was
added depending upon the sample being prepared. The samples were incubated with the
StrepTactin beads for one hour at 4°C and the resulting complexes were purified as
described in section 5.1. A summary of the individual samples prepared and tested in this
experiment are shown in Table 5-1
1

scFvs against protein # 1

scFvs against protein # 5

D5
G5
B8-1
A3
F3
F11
B8-5
shewan . extr.
protein #1
protein #5

a
a
a
a

2
a
a
a
a

a

3

a
a
a
a
a

4
a
a
a
a

a
a

5

a
a
a
a

6
a
a
a
a

a
a

spiked with spiked with
specific non specific
protein
protein

Table 5-1. Components added in each of the I.P. experiments. Approximately 0.7µg of each scFv was
used and 1ml of S. oneidensis (1mg/ml)
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The proteins recovered in samples 1 through 4 were analyzed by Coomassie blue
and silver staining. In contrast, the proteins produced in samples 5 and 6 were analyzed
by silver staining and Western Blot. The results are shown in Figure 5-6 A-D.

B

kD

A

2.1

2.2

2.3

250
150

2.4

2.1

2.2

2.3

2.4

100
75
50
37
25
20
15
10

C

D

kD

2.5

2.6

250
150
100
75
50
37
25
20
15

2.5

2.6
α-SV5
scFvs
protein #1
protein #5

MW (kD)
25 (LC)
50 (HC)
~35
39
53

10

Figure 5-6: Analysis of the Elutions produced in I.P. experiment #2. Figures 6A and 6B correspond to
samples 1-4 analyzed by SDS PAGE and stained with either Coomassie Blue or Silver respectively.
Samples 3 and 4 are those spiked with the corresponding target protein for each scFv set. Figure 6C
and 6D shows analysis of samples 5 and 6 by Western Blot and silver staining respectively. Samples 5
and 6 were spiked with the corresponding non-target protein for each scFv set.
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The SDS PAGE and silver staining results confirm the presence of the Heavy and
Light chains of the α-SV5 antibody in all samples 1-6, as expected (refer to Figure 5-6A,
5.6B and 5.6D). The additional protein at approximately 35kD represents scFv protein
and is visible in all 6 samples when analyzed by SDS PAGE and Silver Staining. Western
Blot analysis (refer to Figure 5.6C) confirmed that the scFv proteins from samples 5 and
6 were captured and purified during the IP process. In contrast analysis of the spiked,
positive control, samples 3 and 4 do not show recovery of either target antigen #1 or #5 at
the expected size, 39kD and 53kD respectively.

5.4 Discussion
Initially a proof of principle experiment was designed to investigate whether single
or double tag purification would be advantageous for recovery of IP complexes. The
experiment included single or double tag purification of a pre-determined
antibody/antigen complex that was created using two different scFvs, D1.3 and HyHel10,
which are known to recognize different epitopes of the chicken lysozyme antigen9.
The proof of principle experiment was created by mixing the strep-D1.3-SV5 fusion
protein with chicken lysozyme and HyHel10-AP. The IP complex was created to
demonstrate that all three components of the IP complex can be purified, from E.coli cell
extract, using the tag purification system.
Single tag purification was tested using either strep tag II or SV5, fused to D1.3.
Results show that Strep Tag II purification successfully captured the IP complex and
gave a clean product; where only the bands of the two single chains (strep-D1.3-SV5 and
HyHel10-AP) and chicken lysozyme were visible. Single tag purification using SV5 was
also successful but gave a less clean product, as the heavy and light chains of the α-SV5
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antibody were recovered in addition to strep-D1.3-SV5, HyHel10-AP, chicken lysozyme.
The α-SV5 antibody heavy and light chains were also eluted because the strong
interaction between the SV5 tag and the anti-SV5 antibody10 is disrupted by the harsh
elution conditions using acidic buffer and a high concentration of salt.
The results of the proof of principle IP experiment demonstrated that double tag
purification was the best method for purifying IP complex. Purification using double tag
(with each tag at either end of the scFv) ensured that only complexes formed with the
target antigen were captured, as the scFv is full length and not truncated. The results also
allowed the order, in which to carry out the double tag purification, to be determined;
sequential purification using strep tag II followed by SV5. Following the first tag
purification using strep tag II, the IP complex was eluted using mild conditions that
allowed the components to remain intact for further purification. In addition, the strep tag
II purification was cleaner than the SV5 tag purification. The eluted sample produced in
the first tag purification was then subsequently re-purified using SV5 tag. Following
purification with the SV5 tag, the IP complex was eluted under more harsh conditions
that caused the components of the IP complex to dissociate. This was not an issue at this
point of the experiment as the final eluted proteins were analyzed under denaturing
conditions (SDS PAGE analysis).
The volume of the eluted sample, in addition to purity, was also an important
factor in determining the order of the double tag purification. Single purification using
strep tag II produced a clean product that was eluted into a very large volume, which then
required a second purification that recovered the IP complex in a much smaller sample
volume. The combination of the double tag purification provided a very clean product
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(consisting of the 3 IP complex components in addition to the heavy and light chain of
anti α-SV5 antibody) in a very small final volume. It was necessary to elute into a small
volume so the concentration of the IP components would be higher, allowing more
accurate identification of the components by mass spectrometry. When analyzing a ‘real’
IP complex it would be necessary to further identify the individual components of the IP
complex using mass spectrometry
After the IP complex had been captured in the proof of principle experiment, the
double tag purification system (strep tag II and SV5 tag) was applied to try to
immunoprecipitate complexes in a real system using S. oneidensis cell extract. Multiple
(30 and 35) different scFvs were previously selected against two different S. oneidensis
biotinylated proteins using phage display (Refer to chapter 4). Seven and six scFvs
specific for antigen #1 and #5 respectively were cloned into pRosa8-strep vector (Refer
to chapter 3) to allow each scFv to be expressed with both strep tag II (N terminus) and
SV5 tag (C terminus).
Seven scFv clones originally selected against antigen #1 and #5, were expressed
and the proteins were subsequently extracted from the periplasm and purified using NiNTA agarose beads in two different formats, in column and in tips. Both approaches gave
product clean enough to be able to estimate the amount of scFv extracted. The Ni-NTA
purification protocol was not optimized to obtain very pure scFv protein preparations
because the proof of principle experiment required each protein to be spiked into cell
extract that contained an array of different proteins. Column format proved to be more
suitable for this experiment because it allowed larger volumes of extract to be handled.
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The scFv purification was performed to concentrate the proteins for quantification so that
the amount of scFv spiked into the cell extract could be accurately determined.
S. oneidensis bacterial cells were cultured and the cells were lyzed by
homogenization. The amount of protein in the whole cell extract was quantified using the
Bradford assay.
In the first experiment, two different sets of scFvs were prepared according to
their target antigen; protein #1 (A3, D5, F3, G5,) or protein #5 (B8-5, F3, F11). Each
scFv set comprised a number of different scFv clones that were pooled for the purpose of
having a mixture of monoclonal antibodies that could theoretically bind with polyclonal
characteristics.
Each scFv set was incubated with a large volume of S. oneidensis cell extract (10 ml of 1
mg/ml) for two hours at 4°C and then with StrepTactin beads overnight. Following
double tag purification, SDS PAGE analysis (Refer to Figure 5-5) revealed the presence
of two proteins of 50kDa and 25kDa that represented the respective Heavy and Light
chain of the α-SV5 antibody (scFv protein) used to capture the IP complex. However,
further SDS PAGE and Western blot analysis confirmed that no scFv proteins were
recovered following purification. It is likely that no scFv protein was recovered because
the proteins were degraded by naturally occurring proteases in the S. oneidensis cell
extract. By repeating the experiment with one tenth volume of cell extract and by
reducing the incubation time to 1hr, the protease activity could be significantly reduced.
Experiment #2 was repeated with the necessary modifications to prevent degradation of
the scFv proteins.
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In the second experiment the volume of cell extract was reduced to 1 ml and the
StrepTactin bead incubation time was decreased to one hour. Four additional control
samples were included in the experiment; the cell extract was spiked with target or nontarget antigen for each scFv set being analyzed. These samples were included as controls
to confirm the specific interaction of the scFv with target antigen and demonstrate
antigen capture
SDS PAGE and silver staining (Figure 5.6A, 5.6B and 5.6D) of the eluted
samples showed that all 6 contained two proteins of approximately 50kDa and 25kDa,
that correspond to the respective Heavy and Light chains of the α-SV5 antibody used to
capture the IP complex. An additional protein at approximately 35kDa representing scFv
protein was also observed and confirmed by Western Blot analysis (Refer to Figure
5.6C). These results confirm that the scFv proteins were captured and purified from all 6
samples, during the IP process. This result demonstrates that the experimental changes
had a positive effect on reducing protease activity and allowing the scFv proteins to be
captured during the double tag purification process.
Despite the success in recovering scFv protein from the cell extract, the results of
the ‘spiked’ positive control samples 3 and 4 (Figure 5.6A and 5.6B) show that the scFvs
were not recovered in complex with either target antigen #1 or #5 at the expected size,
39kDa and 53kDa respectively. Silver staining (refer to Figure 5.6B and 5.6D) did reveal
extra protein bands, in addition to those representing the Heavy and Light chains of the
α-SV5 antibody and the scFv protein. However, the banding did not correlate between
samples as the same pattern of bands was observed in samples that were spiked with
target antigen as well as those that were not.
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There are several reasons why this IP experiment was not successful in the
recovery of protein complexes. It is possible that the scFv protein does not bind to the
non-biotinylated form of the target antigen. Originally, the scFv proteins were selected
against biotinylated antigen. The biotin molecule, could in theory, be an important
residue at the binding site. However, the biotin molecule is small (0.2kD) and it is very
unlikely its presence or absence would have such a significant impact on the binding
interaction between the scFv and biotinylated antigen.
It is possible that target antigen proteins have been captured and recovered at
levels that are beyond detection by SDS PAGE and silver stain analysis. If this is the
case, methods of IP analysis would require further work to investigate more sensitive
ways to detect the presence of the captured proteins. It is also possible that these proteins
are not expressed under the culture conditions we used in this experiment.
The affinity of the binding interaction between the target antigen and each
individual scFv is unknown at present. Affinity studies were not carried out due to
limited availability of target antigen. The stocks of antigen were used for the phagedisplay biopanning and subsequent screening by ELISA, for the identification of positive
binding events. ELISA consumes vast amounts of antigen and this is why some screening
was carried out using flow cytometry because the antigen consumption is significantly
reduced. As a result the antigen resource was limited to certain experiments and was not
available for affinity studies. Nevertheless, the affinity of the scFv for the target antigen
is an important factor in the generation of capture antibodies. If a scFv has a very low
affinity for the target antigen then it is possible that the antigen was initially captured in
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complex but was not recovered following purification because it was washed away prior
to elution.

5.5 Conclusion:
Proteins form part of interaction networks in which the interactions are responsible
for regulation and function. The knowledge of the interaction between proteins in these
networks can help understand the cellular machinery. Although multiple methods to
study protein-protein interaction have been developed, only two groups (Gavin et al and
Ho et al) have done high throughput studies based on in vivo complexes (as opposed to
yeast two hybrid methods) where they have identified unprecedented amounts of
interaction information. Both methods are based on the use of a tagged bait protein which
is used to pull down a protein complex. Comparison of the results obtained between these
two methods and with other methods, where only single protein-protein interaction was
studied (e.g. yeast two hybrid), have yielded poor overlap between them. Although this
could be explained due to each method studying different properties, it is also known that
half of the current high-throughput data are spurious11. For this reason there is a need to
develop as many complementary methods as possible, to increase the confidence in
identified interactions. The method proposed in this thesis involves the use of scFv
antibodies to capture the bait protein and pull down complexes formed with any other
proteins. The main advantage of this system is that the bait protein is not genetically
modified and remains in its natural conformation. This is an essential factor when
investigating complicated protein interactions and elucidating the significance of their
biological role. This method also involves the use of a double tag system (strep tag II,
SV5 tag) which allows for the double purification of protein complexes. The first
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purification step is done under physiological conditions allowing the complex to remain
intact and undergo a second purification step. In the second purification, the high affinity
of the tag (SV5) towards the antibody in the matrix allows the recovery of probably most
of the complex, while the format used (Phynexus tips) allows the elution in a very small
volume which is ideal for later analysis. Despite the problems faced in these studies,
double tag purification using scFv proteins continues to be a feasible method for the
capture of IP complexes, and the work described in this thesis provides the experimental
framework and underpinning to further these studies. Although additional analytical
experiments will be required to investigate the factors required for successful capture and
recovery of IP complexes using this system, we believe the basic structure of the
approach has been defined. Further studies will be needed to investigate the interaction
between the selected scFvs and purified Shewanella proteins, and more sensitive
analytical techniques will have to be applied for the detection and identification of IP
complex components, including LC-MS/MS.
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